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ABSTRACT OF DISSERTATION

COGNITIVE THERAPY FOR THE TREATMENT OF DEPRESSIVE SYMPTOMS
IN PATIENTS WITH HEART FAILURE
Depressive symptoms are common in patients with heart failure (HF) and
adversely affect mortality, morbidity, and health-related quality of life. Cognitive therapy
(CT) has been proposed as a non-pharmacological treatment for depressive symptoms
in patients with HF. However, there is currently little evidence to support use of CT in
patients with HF.
The purpose of this dissertation was to develop and test a brief, nurse-delivered
CT intervention for the treatment of depressive symptoms in patients with HF. Prior to
testing the intervention, preliminary work was conducted resulting in four manuscripts: 1)
a review of the evidence for CT in treating depressive symptoms in patients with
cardiovascular conditions, 2) a description of living with depressive symptoms in patients
with HF and strategies that could be used to manage these symptoms, 3) a review of
measures of negative thinking and the identification of a measure of negative thinking
that can be used in patients with HF, and 4) an evaluation of the psychometric properties
of this measure. Based on information from these manuscripts, a randomized, controlled
pilot study was conducted to test the effects of a brief CT intervention on outcomes of
hospitalized patients with HF who report depressive symptoms.
Forty-two hospitalized patients with HF with mild-moderate depressive
symptoms were randomized to a brief CT intervention focused on reducing negative
thoughts with thought-stopping and affirmations, or to usual care control. Both groups
experienced improvements in depressive symptoms, health-related quality of life, and
negative thinking at one week and three months. However, the intervention group
experienced longer cardiac event-free survival and fewer cardiovascular hospitalizations
and emergency department visits at three months when compared to the control group.
This dissertation has fulfilled an important gap in the evidence base for
depression treatment in patients with HF by demonstrating that a nurse-delivered, brief
CT intervention may improve cardiac event-free survival in patients with HF. This brief
CT intervention is replicable, practical, can be delivered by acute care nurses, and may
improve clinical outcomes in patients with HF. Additional research is needed to
determine the effects of the intervention on long-term outcomes in patients with HF
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CHAPTER ONE:
Introduction
1. Depression in patients with heart failure
Heart failure (HF) is a chronic syndrome which affects 5.8 million people in the
United States (U.S.).1 Age-adjusted five-year survival rates for individuals with HF have
improved from 43% in 1979-1984 to 52% in 1996-2000.2 Unfortunately, despite
improved survival, patients with HF continue to experience high morbidity in the form of
frequent hospitalizations. The diagnosis of HF is the most common reason for
hospitalization among elderly adults in the U.S.,3 and HF currently accounts for 1.08
million hospital discharges per year—a 171% increase since 1979.1
In addition to high morbidity rates, patients with HF frequently experience major
depressive disorder and depressive symptoms. In a meta-analysis of data from 23
studies with over 10,000 participants with HF, researchers estimated that the prevalence
of major depressive disorder, as determined by a diagnostic clinical interview, was 20%
in outpatients and inpatients with HF. When researchers used a more liberal estimate
(self-reported depression questionnaire), the prevalence rate of depressive symptoms
was 30%.4
Both major depressive disorder and self-reported depressive symptoms have
significant clinical consequences in patients with HF. Patients with HF who have
depressive symptoms are twice as likely to die and two and a half times more likely to be
re-hospitalized than patients who do not have depressive symptoms.4 Researchers have
also demonstrated a dose-response relationship between depressive symptoms and
long-term survival in patients with HF. Patients with mild, moderate, and severe
depressive symptoms as measured by the Beck Depression Inventory are respectively,
21%, 53%, and 83% more likely to die during a seven-year follow-up period than
patients who have no depressive symptoms.5
The reasons for the association between depressive symptoms and shortened
survival in patients with HF are unclear. Depression and HF are two conditions that
share important pathophysiological and behavioral links. Researchers have suggested
that depression in patients with HF may be associated with proinflammatory cytokines,
arrhythmias, sympathetic nervous system activation, and increased platelet aggregation,
all of which may worsen the course of HF. Furthermore, depression may contribute to
poor outcomes in HF via behavioral links such as non-adherence and poor social
support.6
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Researchers have found that the presence of depressive symptoms is an
independent predictor of worsened health-related quality of life (HRQOL) in patients with
HF.7, 8 HRQOL is a subjective, patient-centered outcome that refers to how a health
condition affects a person’s total well-being. Researchers are beginning to recognize
that HRQOL may be more important than quantity of life,9 given that patients with HF are
experiencing longer survival and must adjust to life with a chronic health condition.
The problems associated with depressive symptoms in patients with HF have
been well-described. However, there is a lack of research testing interventions for
depressive symptoms in patients with HF.10 Given the significant clinical consequences
of depressive symptoms in patients with HF, it is imperative that researchers develop
and test interventions for the treatment of depressive symptoms in patients with HF.
2. Treatment of depressive symptoms in patients with heart failure
The 2009 guidelines for HF management from the American College of
Cardiology and the American Heart Association provide no direction for the treatment of
depression in patients with HF. The guidelines state, “Good evidence exists for the
critical importance of delivering comprehensive supportive care to these patients,
including the assessment and treatment of… depression.”11 The lack of specificity in
these guidelines reflects the state of the science regarding the treatment of depression
in patients with HF, as there has been insufficient research on treatments for depressive
symptoms in patients with HF.
In the general population, evidence suggests that current pharmacological
treatments for depression are only modestly effective compared to placebo. In 2008,
Kirsch et al.12 conducted a meta-analysis examining antidepressant efficacy using
clinical trial data submitted to the Federal Food and Drug Administration and obtained
with the Open Records Act. The authors found that among patients with moderate
depression, there was a statistically significant difference between antidepressant and
placebo use, but this difference did not meet criteria for clinical significance. Both drug
and placebo resulted in modest improvements in depression. Among patients with the
most severe levels of depression, antidepressant use resulted in a statistically and
clinically significant improvement in depression compared to placebo. However, the
researchers proposed that this improvement could have been due to a reduced placebo
effect among the severely depressed, rather than an antidepressant effect.
Likewise, in the only randomized, controlled trial to date to test the effects of
antidepressant therapy on depression in patients with HF (SADHART-HF), O’Connor et
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al.13 found that depressed patients with HF who received antidepressants did not
experience a statistically significant improvement compared to placebo. However, both
the intervention group and the placebo group received a nursing intervention as a part of
the study protocol, and both groups experienced considerable reductions in depressive
symptoms. The nursing intervention consisted of one-hour telephone counseling
sessions that took place every other week for sixteen weeks and were delivered by a
psychiatric nurse (Personal communication, C. O’Connor, March 3, 2010). The authors
suggest that the nursing intervention was so powerful that the effects of the nursing
intervention obscured any effect of the antidepressant.
The results of the SADHART-HF trial13 suggest that non-pharmacological
interventions carried out by nurses may be effective for the treatment of depressive
symptoms in patients with HF. Non-pharmacological interventions have several
advantages over pharmacological treatments such as a lack of drug-drug interactions,
immediate short-term relief of symptoms, and greater involvement of patients in their
own self-care.
Cognitive Therapy (CT) is a non-pharmacological intervention for depression that
was developed by Beck in 1967,14 has been used successfully to treat depression in
multiple populations,15 and may be useful for treating depression in patients with HF.
Nurses can be trained to administer CT as a nursing intervention. Cognitive Therapy is
compatible with common nursing interventions such as teaching patients to accurately
appraise stressors, determining the best coping method, and increasing perceived
control.16
Beck’s cognitive model of depression provides the theoretical basis for CT. The
main tenet of the cognitive model is that negative thinking influences the emotional,
behavioral, and somatic symptoms associated with depression.17 Negative thinking can
be defined as cognitions about the self, world, future, and interpersonal relationships.18
Negative thinking originates in childhood and dominates the perceptions of the
depressed individual.19 Examples of negative thoughts include, “I’m worthless,”
“Everything I do is a failure,” and “Nothing’s ever going to work out for me.”18 Negative
thinking occurs automatically and persists over time. Although the content of negative
thoughts is irrational, these thoughts are believable to the person experiencing them.14
The goal of CT is to reduce depressive symptoms by redirecting negative
thinking. During CT, the therapist teaches the client to identify, analyze, and question
negative thoughts. For example, the therapist helps the client identify negative thoughts
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such as “I’m a burden to my family.” Together, the therapist and the client explore the
evidence for the negative thought. After evaluating the thought, the therapist guides the
client to challenge the thought. By challenging and changing thoughts, the client is able
to modify negative emotions and behaviors.17 Although CT holds promise as a potential
treatment for depressive symptoms in patients with HF, research is needed to
demonstrate its efficacy as a treatment for depressive symptoms in patients with HF.
Therefore, the purpose of this dissertation was to develop and test a CT
intervention for managing depressive symptoms in patients with HF. The chapters of this
dissertation represent the systematic development of my initial program of research.
First, a review of the literature was performed to establish the evidence for CT as a
treatment for depressive symptoms in patients with HF. Second, a qualitative research
study was conducted that identified negative thinking as an important target for a CTbased intervention that would be appropriate for patients with HF. Third, a critical review
of the literature was conducted to identify the best instrument for measuring negative
thinking in patients with HF. Fourth, evidence was provided for the reliability and validity
of the selected measure of negative thinking in patients with HF. And finally, a clinically
feasible, brief CT intervention for depressive symptoms targeting negative thinking in
patients with HF was tested in a randomized clinical trial.
3. Summary of subsequent chapters
Chapter Two is the critical review of the literature20 to determine the empirical
support for the use of CT in patients with HF. Because there was limited research on CT
in patients with HF, the review was expanded to include research studies CT across all
cardiovascular-related conditions. Insights from these studies were interpreted with
respect to applicability to patients with HF. Electronic databases were searched from
1980 through 2009 using the following key words: depression, cognitive therapy,
cardiovascular, diabetes, and stroke. Articles were included if they met the following
criteria: randomized, controlled trial; cognitive therapy intervention; depression or
depressive symptoms measured as an outcome; sample consisted of patients with
cardiovascular disease, non-hemorrhagic stroke, or diabetes. Fourteen articles met the
inclusion criteria and were extracted for review. Positive effects of CT on depression or
depressive symptoms were reported in eight of the fourteen studies. Possible reasons
for the mixed results, as well as recommendations for the design of future studies testing
CT in patients with HF are provided.
Chapter Three is the qualitative research study21 conducted to obtain information
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needed to guide the development of a CT intervention for depressive symptoms in
patients with HF. The research questions in this qualitative descriptive study were: How
do persons with HF describe their depressive symptoms? What strategies do they use to
reduce depressive symptoms? The sample consisted of ten outpatients with chronic HF
who had clinically significant depressive symptoms as measured by the Beck
Depression Inventory version II or a history of depression. Data were collected via taped,
individual, 30-60 minute interviews which took place in the participants’ homes. Content
analysis was conducted using the qualitative software ATLAS ti (v5). The participants
identified negative thoughts that exacerbated their depressed mood. The most frequently
mentioned strategy that participants used to manage their depressive symptoms was
positive thinking, which included the use of affirmations. The findings from this study
were used to develop a brief CT intervention which will be presented in Chapter Six.
Chapter Four is the critical review and analysis22 of three measures of negative
thinking to identify the best instrument for measurement of negative thinking in patients
with HF. Three of the most widely used instruments that measure negative thinking were
selected for review: the Crandell Cognitions Inventory, Automatic Thoughts
Questionnaire, and Cognitive Checklist- Depression. The three instruments were
described and their strengths and weaknesses were systematically compared, with
particular attention to strength of evidence for reliability and validity. The Crandell
Cognitions Inventory was identified as the instrument that has the best potential for
measuring negative thinking in patients with HF, and recommendations for future
psychometric testing were provided.
Chapter Five is the report on the psychometric properties of the Crandell
Cognitions Inventory (CCI) in patients with HF, to establish reliability and validity of this
measure of negative thinking in patients with HF. The purpose of this study was to
evaluate the internal consistency reliability and construct validity of the CCI in patients
with HF. Cross-sectional questionnaire data were collected from 179 outpatients with HF
using the CCI, Beck Depression Inventory-II, and Brief Symptom Inventory- anxiety
subscale. Reliability was assessed with Cronbach’s alpha; construct validity was
evaluated with factor analysis and hypothesis testing. The findings provided evidence for
the reliability and validity of the CCI for measuring negative thinking in patients with HF.
Chapter Six presents the findings of the randomized, controlled pilot study testing
a brief CT intervention in hospitalized patients with HF. Patients were eligible to
participate if they were admitted to the hospital with a diagnosis of HF and were
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experiencing mild to moderate depressive symptoms as measured by the Beck
Depression Inventory-II. A total of forty-two patients were randomized to the intervention
and control groups. The intervention group received a single 30-minute brief CT
intervention at the bedside and a one-week telephone booster, and the control group
received usual care. Depressive symptoms, negative thinking, and HRQOL were
measured at baseline, one week, and three months. Three-month cardiac event-free
survival data were also collected by patient interview and hospital record review. The
results showed that both groups experienced significant improvements in depressive
symptoms, negative thinking, and HRQOL over time. However, the intervention group
experienced longer cardiac event-free survival compared to the usual care group (80%
alive without a cardiac event vs. 40%, p = .048).
Chapter Seven is an integrated discussion in which the prior chapters of this
dissertation are synthesized to advance the state of the science of treatment of
depressive symptoms in patients with HF and make recommendations for practice and
future research.

Copyright © Rebecca L. Dekker 2010
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CHAPTER TWO:
Cognitive Therapy for Depressive Symptoms in Patients with Heart Failure:
A Critical Review
1. Introduction
Depression is a significant problem in patients with heart failure (HF). One in five
persons with HF has clinical depression,1 and up to 48% have clinically significant
depressive symptoms.2 According to the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV-TR), a major depressive episode, sometimes referred
to as clinical depression, consists of five or more symptoms which are present for most
of the day, almost daily, for at least two weeks. One of these symptoms must be either
depressed mood or loss of interest or pleasure in usual activities, and the symptoms
must cause significant distress in social, occupational, or other areas of functioning
(Table 2.1).3 However, patients can experience clinically significant depressive
symptoms without the presence of major depressive disorder.4 Depressive symptoms
may include depressed mood, irritability, guilt, hopelessness, low self-esteem, fatigue,
sleep disturbances, appetite change, and inability to concentrate.5
The adverse effects of clinical depression and depressive symptoms on mortality
and hospitalizations in patients with HF have been well documented.1, 2, 6-8 Results from
a recent meta-analysis demonstrated that patients with HF who have depressive
symptoms are more than twice as likely to die or experience a cardiac event compared
to patients without depressive symptoms.1 Moreover, the presence of depressive
symptoms has a negative impact on every dimension of health-related quality of life in
patients with HF, including physical functioning, social functioning, and mental health.2
The problems associated with depression and depressive symptoms in patients
with HF are well described. It is time for researchers to test interventions. Importantly,
there is a lack of research on non-pharmacological interventions for depressive
symptoms in patients with HF.9 Cognitive therapy (CT) has been used successfully to
treat depression in multiple populations.10, 11 Therefore, it may also be useful for treating
depression in patients with cardiovascular illnesses, including HF. The purpose of this
critical review was to examine the empirical support for the use of CT in treating
depression and depressive symptoms in patients with cardiovascular-related illnesses.
2. Background
Beck, a psychiatrist, developed the Cognitive Model of depression in 1967 to
explain the psychological processes that occur in depression. The underlying
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assumption behind the Cognitive Model was that human minds are biased and cannot
interpret stimuli objectively. This bias leads to cognitive errors, or dysfunctional
thinking.10 The Cognitive Model holds that dysfunctional thinking influences the
emotions, behaviors, and psychosomatic symptoms associated with depression. Thus,
interventions aimed at changing dysfunctional thinking should improve the emotional,
behavioral, and somatic symptoms of depression.11
Cognitive therapy, also referred to as cognitive behavioral therapy, is the
psychotherapeutic intervention based on the Cognitive Model of depression. The primary
goal of CT is to alter emotions and behavior by redirecting negative cognitive processes.
CT is typically a short term therapy that consists of 4 to 14 sessions, depending on the
individual’s progress. The role of the therapist is to develop a collaborative, therapeutic
relationship with the client and to teach the client to become his or her own therapist.
The therapist teaches the client to identify, analyze, and question dysfunctional thinking.
For example, the therapist may help the client to identify negative thoughts such as “I’m
a burden to others.” Together, the therapist and the client explore the evidence behind
this negative thought. After evaluating the rationale for the thought, the therapist then
guides the client to challenge the thought, and eventually change the client’s thinking. By
creating changes in thinking, the client may modify negative emotions and behaviors.11
CT offers several potential advantages for the treatment of depression and
depressive symptoms in patients with HF. First, CT is a non-pharmacological
intervention. Non-pharmacological interventions may have several advantages over
pharmacological treatments such as a lack of drug-drug interactions, immediate shortterm relief of symptoms, and greater involvement of patients in their own self-care.
Second, CT is an intervention that nurses can be trained to administer. CT is compatible
with common nursing interventions of teaching patients to accurately appraise stressors,
determining the best coping method, and increasing perceived control. Despite the
potential benefits of CT, its effectiveness in patients with cardiovascular illness including
HF remains unknown. The following review provides a critical analysis of the existing
research on the effectiveness of CT for treating depression or depressive symptoms in
patients with cardiovascular illnesses.
3. Methods
The databases searched for relevant literature were PUBMED, PsychInfo,
CINAHL, and MEDLINE. Keywords included depress* and cognitive therapy (or
cognitive behavioral therapy) and cardiovascular (or heart failure, chronic illness,
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coronary artery disease, cardiac, stroke, or diabetes). The search was limited to English
language papers published between 1980 and 2009.
Studies were included in the review if they met the following criteria: randomized,
controlled trial; a cognitive therapy intervention; depression or depressive symptoms
measured as an outcome; sample consisted of patients with cardiovascular disease,
non-hemorrhagic stroke, or diabetes. Diabetes mellitus commonly coexists with HF12
and is an important risk factor for the development of HF.13 Thus samples that contained
patients with diabetes were also included.
The search resulted in 335 articles of which the titles or abstracts were screened
for inclusion criteria. Reference lists of relevant articles were screened for additional
studies. A total of fourteen papers met the inclusion criteria and were extracted for
review.
4. Results
4.1. Cardiovascular disease
Eight studies were identified in which the impact of CT on depression in patients
with cardiovascular illness was evaluated (Table 2.2).
In the largest randomized controlled trial on CT in cardiovascular disease to date,
the ENRICHD (Enhancing Recovery in Coronary Heart Disease) investigators14
compared the impact of CT with usual care on depressive symptoms and event-free
survival in 2,481 patients with a recent myocardial infarction (MI). Patients were eligible
to participate if they were defined as depressed on a diagnostic interview or if they had
low perceived social support. Patients in the intervention group attended 6 to 19
individual or group CT sessions (median of 11 sessions) over six months in conjunction
with selective serotonin reuptake inhibitor when indicated. The intervention group
experienced a statistically significant decrease in depressive symptoms compared to the
control group at six months. However, this difference was no longer present at 30 or 42
months of follow up. There was no difference in event-free survival between the
intervention and control groups.
The lack of impact on event-free survival may have been due to several factors.
The ENRICHD investigators assumed that CT should begin as soon as possible (within
28 days) after an MI. Thus, the study may have included patients in the control group
who had transient rather than clinical depression and recovered without intervention.
The investigators also assumed that the usual care group would not receive treatment
for depression, but this was not the case. Antidepressant use was comparable in the
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control group (21%) and intervention group (28%).14-16 It is not known why a decrease in
depressive symptoms in the intervention group in this study did not translate into
improved outcomes. It may be that the decrease in depressive symptoms was
insufficient to affect clinical outcomes. This conclusion is supported by the observation
that while depressive symptoms in the intervention group decreased by 49%, depressive
symptoms in the control group also decreased by 33%.14
More recently, Freedland et al. 17 compared the effects of CT, supportive stress
management, and usual care for the treatment of depression in 123 patients who were
post coronary artery bypass graft surgery (CABG). Patients were included if they scored
10 or higher on the Beck Depression Inventory (BDI) and met the DSM-IV criteria for
depression based on a diagnostic interview. The investigators tested two separate
interventions: 12 weeks of CT and 12 weeks of supportive stress management
(progressive relaxation, controlled breathing, and imagery); both interventions were
delivered in individual sessions by a trained clinical social worker or psychologist.
Follow-up information on depression was collected at 3, 6, and 9 months using the BDI
and the Hamilton Rating Scale for Depression.
The investigators found that patients in both intervention groups were more likely
to experience remission from depression at all time points compared to patients in the
usual care group. At nine months, 73% of the CT group and 57% of the stress
management group experienced remission from depression, compared to 23% of
patients in the usual care group (p = .003). This study was underpowered to detect
differences between the CT and stress management arms of the study. Therefore, it is
difficult to draw conclusions as to whether CT or stress management was superior for
the treatment of depression in patients who are post-CABG. However, patients who
received CT experienced greater improvement in secondary outcomes such as lower
anxiety, hopelessness, and perceived stress; these results suggest that CT may offer
more benefits to patients in comparison to stress management.
Twenty years ago, Burgess et al.18 reported that an intervention combining CT,
social support, and job return counseling failed to reduce depressive symptoms in
patients who had recently experienced an acute MI. In this randomized, controlled trial,
180 patients were randomized to the intervention group or usual care. There were no
differences in depression scores between groups at baseline, three months, or thirteen
months of follow-up. The authors did not offer any explanations for the null effects on
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depression. Females were underrepresented in the study; thus, it is not known whether
the intervention would have been effective for females.
CT may be effective in reducing depressive symptoms in survivors of sudden
cardiac death. Cowan et al19, 20 tested the impact of CT, biofeedback therapy, and health
education on depressive symptoms and mortality in 133 survivors of sudden cardiac
death. Only 11% of the sample had depressive symptoms at baseline and all of these
were male. Approximately half of the sample had chronic heart failure (NYHA Functional
Class II-IV). The treatment group experienced a significant decrease in depressive
symptoms compared to the control group. Although the study was not originally powered
to detect differences in mortality, the treatment group experienced an 86% reduction in
the risk of cardiac death compared to the control group. Therefore, the results of this
study suggest that CT and biofeedback may be beneficial for survivors of sudden
cardiac death, whether or not they are experiencing depressive symptoms.
Limited evidence suggests that CT may be more effective than exercise at
reducing depressive symptoms in patients with coronary artery disease. Black et al21
randomized 60 patients who had recently been hospitalized for a coronary event and
were psychologically distressed to one of two groups: a special intervention that
consisted of stress management, relaxation training, and CT administered by a
psychiatrist, or a cardiac rehabilitation group that included exercise and risk reduction
counseling. At six months, the CT group experienced a significant reduction in
depressive symptoms compared to the cardiac rehabilitation group. There was no
difference between groups with regard to rehospitalizations. There were several
limitations of the study such as low representation of women (12%), exclusion of elderly
(>80 years old), and lack of a true control group. Most importantly, adherence to the
intervention was low. Less than 50% of participants attended more than one intervention
session. Crossover between groups was also a problem, as six participants in the usual
care group were treated with antidepressants or psychological counseling. Combined,
these limitations severely weakened the internal and external validity of the study.
Results from three studies suggest that CT may be helpful for reducing
depressive symptoms in patients with implanted cardioverter defibrillators (ICDs).
Frizelle et al.22 compared the impact of a cardiac rehabilitation and CT to a wait list
control group on depressive symptoms in patients with ICDs. Despite the small sample
size (N = 22), the intervention group experienced a significant reduction in depressive
symptoms compared to the control group at three months. The intervention included
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exercise, which makes it impossible to ascertain whether the CT alone had an impact on
depressive symptoms.
In another study, Kohn et al.23 evaluated the effects of CT on depressive
symptoms in 49 patients with ICDs. This study was limited by the lack of a
comprehensive measure of depressive symptoms at baseline. Only three biological
indicators of depression were measured at baseline: sexual functioning difficulties,
changes in appetite, and sleep disturbance. At nine months follow-up, the CT group
reported fewer sexual functioning difficulties than the control group; however, sexual
difficulties increased in both groups over time. The BDI version II (BDI-II) was
administered only at follow-up. Although the CT group had a lower BDI-II score than the
control group at follow-up, the lack of depression score data at baseline limits the
conclusions that can be drawn from findings.
Lewin et al.24 tested the effects of a brief, self-help CT booklet for the treatment
of depressive symptoms in patients who were undergoing ICD implantation. In this RCT,
eight ICD implantation centers were randomized to intervention or control. The
intervention consisted of several booklets that were given to the patient and family by
healthcare providers who had received a half day of training in administering the
intervention. One of the booklets consisted of a self-help cognitive behavioral
rehabilitation program, but the intervention in this booklet was not described in further
detail. Patients in the intervention arm also received three phone contacts after ICD
implantation to discuss their progress and set goals. The authors defined depression as
a HADS score of 8 or greater, and patients were followed for six months.
In a logistic regression, the investigators found that patients in the intervention
group were less likely to experience depression at six months compared to patients from
control centers, after adjusting for baseline depression score (OR -0.46, Confidence
interval -1.93 to 1.00). Furthermore, the intervention group had a greater reduction in the
proportion of patients with depression at six months compared to the control group (13.2% vs. -2.1%, p value not specified). However, this study was limited by the lack of a
thorough description of the CT intervention, which limits researchers’ ability to replicate
the results and translate the study findings to the clinical setting.
Finally, results from a small study suggest that an intense regimen of CT
combined with exercise may reduce depressive symptoms in patients with heart failure
(HF).25 In this study, 20 patients with HF (NYHA Class II/III) were randomized to three
groups: group-based CT plus exercise, Digoxin titrated to achieve drug levels between
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0.8 – 2.0 ng/mL, or placebo. Despite the small sample size, the intervention group
experienced a 52% reduction in depressive symptoms while the other groups
experienced a 15% and 25% increase in depressive symptoms, respectively. As a result
of the combination of exercise with CT, it is not known whether CT alone would have
been effective in decreasing depressive symptoms. In addition, the follow up period was
short, only 12 weeks, and therefore no conclusions can be drawn regarding the longterm effects of the intervention.
4.2. Stroke
There is less evidence regarding the effectiveness of CT on depression in
patients with stroke. Lincoln and Flannaghan26 conducted a randomized, controlled trial
in which 123 patients who had recently experienced a stroke and depressive symptoms
(scored > 10 on the BDI) were assigned to one of three groups: CT, an attention placebo
group, or a control group. Surprisingly, depressive symptoms improved over time in all of
the groups. There were no significant differences between the groups at baseline, three
months, and six months of follow up.
The authors suggested that the intervention, which consisted of ten one-hour
sessions, may not have been intense enough to improve depressive symptoms more
than would occur naturally. However, other investigators have tested CT in chronic
illness and found positive results using a similar number of CT sessions.14, 27 It is
possible that the improvement in depressive symptoms in all three groups over time may
have reflected the natural improvement of depression that occurs over time after an
acute stroke.26
4.3. Diabetes
The effectiveness of CT for the management of depression in patients with
diabetes has been tested in four randomized, controlled trials. Lustman et al.27
conducted a RCT in which 51 patients with type 2 diabetes and clinical depression were
assigned to either ten weeks of CT and diabetes education or an education-only group.
As a result of the intervention, the treatment group had a higher rate of remission from
depression compared to the control group (58.3% vs. 25.9%).
In contrast, investigators from three studies have found that CT was not effective
for treating depressive symptoms in adults with diabetes. Snoek et al.28 compared the
effects of two interventions on depressive symptoms in adults with type 2 diabetes. The
two interventions that were compared were a six week group CT intervention and a
blood glucose awareness training. The results showed no differences between groups at
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6 and 12 months follow up. There was no true usual care group; by comparing two
active interventions, the investigators may have been less likely to detect a difference in
the improvement of depressive symptoms between groups.
Similarly, Henry et al.29 also found that CT did not improve depressive symptoms
in patients with type 2 diabetes. The investigators in this small RCT used a wait list
control to evaluate the effects of CT plus progressive muscle relaxation on depressive
symptoms in nineteen patients with type 2 diabetes and elevated levels of glycosylated
hemoglobin. Although there was an overall decrease in depressive symptoms from pretreatment to post-treatment in both the intervention and wait-list groups, there was no
difference between groups. Because of the small sample size, the study likely was
under-powered to detect changes in depressive symptoms between groups.
In a much larger study of 344 adults with type 1 diabetes, Ismail et al.30 also
found that CT did not improve depressive symptoms. In this RCT, the investigators
compared CT plus motivational enhancement therapy and motivational enhancement
therapy alone to usual care in the treatment of depressive symptoms. Despite the
lengthy intervention (up to 12 sessions over 6 months), a large sample size, and a
rigorous design, neither of the intervention groups experienced a greater reduction in
depressive symptoms over time than the usual care group.
5. Discussion
5.1. Discussion of findings
Fourteen randomized, controlled trials were identified in which investigators
tested the impact of CT on depression or depressive symptoms in patients with
cardiovascular-related illnesses. Positive effects of CT on depression or depressive
symptoms were reported in eight of the fourteen studies. This discussion section will
report possible reasons for the mixed results, as well as limitations that prevent wide
generalization of study findings.
The major factors that contributed to the mixed results were that: 1) more than
one intervention was tested in most studies, 2) there was a lack of a true, no-intervention
control group in most studies, 3) most had small sample sizes, and 4) follow-up periods
were short. The consequences of each of these factors are described below.
The presence of more than one treatment intervention in several studies
restricted the ability to determine the effect of CT on outcomes. In two studies which
found positive outcomes, CT and antidepressant therapy were combined,14, 21 making it
impossible to determine the effect of CT alone on depressive symptoms. Similarly, in two
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other studies finding positive outcomes, the intervention consisted of CT plus exercise.22,
25

Although combined interventions may be a valuable addition to the treatment options

for depressive symptoms in patients with cardiovascular disease, it is difficult to assess
the value of CT by itself when it is tested in combination with other interventions. For
example, a growing body of evidence has demonstrated that exercise is an effective
treatment for persons with major depressive disorders or with depressive symptoms.31, 32
Thus exercise in combination with CT may have yielded a larger effect than CT alone or
may obscure the effect of CT.
Six of the fourteen studies lacked a true, no-intervention group. These studies
included a variety of comparison groups. For example, one group of investigators
compared patients who received a CT intervention to patients who received a cardiac
rehabilitation exercise intervention.21 Although these investigators found positive results
with the CT intervention, the comparison of CT to exercise may have yielded a smaller
effect than would have been seen if the investigators compared CT to a third, true
control group.
Seven of the fourteen studies had small sample sizes (total N ranging from 19 to
86), and eight studies had a follow-up period of six months or less. Interestingly, despite
the ENRICHD trial’s large sample size and long follow up period (30 months), the
investigators found only modest clinically significant reductions in depressive symptoms.
Moreover, this benefit was no longer present by 30 months of follow-up, as all groups
improved over time.14 In contrast, researchers of smaller studies found that CT reduced
depressive symptoms at a relatively short follow-up time. It is possible that the
improvements in depressive symptoms found in these studies did not persist. Short
follow-up times limit the ability of researchers to determine whether CT is a potential
long-term treatment for depression.
Researchers’ ability to generalize the findings of several of the reviewed studies
is compromised by several factors: 1) vaguely described interventions, 2)
underrepresentation of women, 3) use of a wide variety of instruments to measure
depressive symptoms, and 4) failure to adhere to the CONSORT guidelines for the
reporting of clinical trials.
First, researchers often included vague descriptions of the intervention in articles;
this limits the ability of future researchers to replicate results from these studies as well
as translate the findings to clinical practice. It is also possible that the investigators
tested different forms of CT, which could contribute to the mixed findings.
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Second, only nine of the fourteen studies had samples that consisted of at least
30% women. Of these nine studies, investigators in four studies found that CT reduced
depressive symptoms. Previous researchers demonstrated that women may react
differently to psychological interventions than men. In a post-hoc analysis, the ENRICHD
investigators reported that white men who received the CT intervention had a reduced
risk of experiencing cardiac mortality or recurrent MI. In contrast, there was no similar
beneficial effect for women and minorities.33 Frasure-Smith et al.34 reported that women
who received an intense psychosocial nursing intervention after a myocardial infarction
experienced an increase in all-cause mortality when compared to the control group
(10.3% vs. 5.4%). This adverse effect was not found in the male participants. The results
of these two studies suggest that it is important to evaluate the impact of psychological
interventions on both men and women. Overall, the studies in this review provide
insufficient evidence to determine the impact of CT on depressive symptoms in women
with cardiovascular disease.
Third, researchers used a variety of methods to measure clinical depression and
depressive symptoms. Many of these measures, such as the Beck Depression
Inventory, have established reliability and validity. In contrast, Kohn et al.23 used an
instrument that measured three biological indicators of depression. The reliability and
validity of this instrument was not provided. Overall, there was a lack of consistency on
the measurement of depression in the reviewed studies. This limitation may restrict
researchers from conducting future meta-analyses to examine the overall effect of CT for
the treatment of depression in patients with cardiovascular disease. For this reason, in
2006 a working group of the National Heart, Lung, and Blood Institute made
recommendations as to which instruments researchers should use to measure
depressive symptoms in clinical trials that include patients with cardiovascular disease.35
Finally, of the twelve studies that were published after 1996, only five followed all
of the CONSORT guidelines.14, 26 The CONSORT (Consolidated Standards of Reporting
Trials) guidelines were originally published in 1996 and have since been revised.36, 37
These guidelines provide a standardized framework for the reporting of clinical trials.
The CONSORT guidelines allow the reader to understand the design, conduct, analysis,
and interpretation of a randomized controlled trial, and to judge whether a trial has
internal or external validity.37 A lack of adherence to the CONSORT guidelines in several
of the studies reduces the transparency of the reported clinical trials and could contribute
to a bias in over-estimating the effects of interventions.
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5.2. Implications for nursing research
The problems associated with depression and depressive symptoms in patients
with HF have been adequately described. Interventions such as CT for the treatment of
depression in patients with HF are now needed to move us forward. As only one small
trial has studied the effects of CT in the treatment of depression in patients with HF, this
article reviewed the empirical evidence for CT in the treatment of depression in patients
with cardiovascular-related illnesses. Overall, the current evidence to support CT as a
treatment for depression or depressive symptoms in patients with cardiovascular-related
illnesses is inconclusive due to limitations of existing studies.
Based on this review, future clinical trials should include the following
recommendations. Researchers should test the effect of a CT intervention alone as well
as in combination with other treatments. The CT intervention should be replicable in a
clinical setting. Careful consideration should be paid to the inclusion of an appropriate
comparison group. Given that depression in patients with HF is associated with a high
risk for morbidity and mortality, it may be unethical to withhold treatment for depression
from patients who are severely depressed. Furthermore, CT alone may not be
appropriate for severely depressed individuals. It is suggested that researchers should
exclude patients with severe depression and instead refer them to their primary care
providers for treatment.
Studies should be designed with sufficient sample sizes to be adequately
powered to detect changes in depressive symptoms and related outcomes. Researchers
should also make special efforts to include a representative sample of women. In
addition, trials should include an adequate follow-up time of at least one year in order to
provide information on the long-term effects of CT on both depression and other health
outcomes, such as morbidity and mortality. It is also important that researchers use
consistent methods for measuring depressive symptoms, such as issued in the National
Heart, Lung, and Blood Institute’s recommendations.35 Finally, to improve transparency
in the reporting of randomized, controlled trials, researchers should follow the
CONSORT guidelines.37.
Several gaps in understanding of CT as a treatment for depression in
cardiovascular conditions, including HF, remain. It is not known if there is a doseresponse relationship between CT and depression in patients with cardiovascular
disease. For example, we do not know how many CT sessions are necessary to improve
depression outcomes, or whether the effective dose varies among different
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cardiovascular populations. The best time to intervene for depressive symptoms in
patients with cardiovascular disease is also unknown. The results of the ENRICHD trial
showed that patients who had recently experienced a cardiac event and received a CT
intervention only experienced a minimal improvement in depressive symptoms. This led
researchers to question whether CT should be offered to patients who have recently
experienced a cardiac event or if treatment should be delayed.15 Likewise, it is not
known whether CT should be offered to patients with HF who have been recently
hospitalized or whether their depression may remit on its own. Next, it is not known
whether CT interventions should be offered only to patients with cardiovascular disease
or HF who are clinically depressed or to all patients, regardless of depression status.
Finally, it is unknown whether CT can affect outcomes related to depression such as
mortality, morbidity, or health-related quality of life in patients with cardiovascular
disease or HF.
5.3. Implications for nursing practice
Cognitive therapy is compatible with nursing practice and has been used
successfully to treat depression in medically-healthy populations. Because there is a
scarcity of evidence for patients with HF, this review was broadened to include all
patients with cardiovascular-related illnesses. Based on the findings of this review, the
current evidence is insufficient to recommend CT as a treatment for depressive
symptoms in patients with cardiovascular illness. Although the majority of the studies
reviewed demonstrated that CT may be effective, the limitations in study design prevent
wide generalization of the results. More evidence is needed before it can be
recommended that nurses routinely refer patients with cardiovascular disease to CT for
the treatment of depression or depressive symptoms. It is important to also note that CT
may not be appropriate for all patients with HF or cardiovascular disease, particularly for
patients with cognitive impairment or those who may have difficulty adhering to the CT
treatment protocol. These patients may benefit from alternative treatments for
depression.
6. Conclusion
Depression is a significant clinical problem in patients with HF. The time has
come for researchers to focus their efforts on designing and testing non-pharmacological
interventions for depression in patients with HF. Cognitive therapy holds promise as an
intervention that may decrease depressive symptoms in patients with cardiovascular
illness including HF. Nurses should continue to monitor the literature for new evidence
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regarding the effectiveness of CT for treating depression in patients with HF and other
cardiovascular disease.
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Table 2.1: DSM-IV-TR criteria for a major depressive episode
At least 5 of the following symptoms have been present most of the day, nearly every
day, during the same 2 week period and represent a change from previous
functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of
interest or pleasure:
1. Depressed mood
2. Loss of interest or pleasure
3. Weight loss or changes in appetite
4. Insomnia or hypersomnia
5. Psychomotor agitation or retardation
6. Fatigue
7. Feelings of worthlessness or guilt
8. Decreased ability to concentrate
9. Thoughts of death, suicidal ideation, or suicide attempt.
•

The symptoms must cause significant impairment in functioning (i.e., work, social)

•

The symptoms must not be directly due to a medical condition (i.e.,
hypothyroidism) or a medication
The episode is not better accounted for by a different diagnosis such as
bereavement, bipolar disorder, or schizoaffective disorder

•

DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
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Table 2.2: Study characteristics and findings
Design,
follow-up
time

First
author
(year)
14

ENRICHD
(2003)

Sample

21

RCT

N = 2481

2 arms

28 days post-MI

30
months

Eligible if
classified as
depressed or
low perceived
social support
Females 44%
Minorities 34%

Measurement
of depression

Treatment

Cardiovascular Disease
DISH, BDI,
11 tailored CT
HRSD
sessions over 6
months, group
therapy as needed,
referral to psychiatry
for antidepressants
as needed

Control

Results

Usual care;
physicians were
notified if patients
were depressed
or had low
perceived social
support

The CT group had a
lower BDI score
compared to control
(9.1 vs. 12.2, p <.001),
and a lower HRSD
score (7.6 vs. 9.4, p
<.001) at 6 months.
This difference was not
present at 30 or 42
months

Table 2.2: (Continued)
First
author
(year)
Freedland
(2009)17

Design,
Sample
follow-up
time
N = 123
RCT
3 arms
9 months

CABG surgery
within the past
year

Measurement
of depression

Treatment

HRSD score
derived from
the DISH; BDI

1. CT: 12 weekly,
individual, 50-60
minute sessions with
a therapist

Control

22

Usual care

Patients in the CT and
stress management
group were more likely
to experience
remission from
depression at 3, 6, and
9 months compared to
patients in the usual
care group

Usual care

There were no
differences between
groups on depression
scores at baseline or
follow-up

2. Supportive stress
management: 12
weekly, individual,
50-60 minute
session. Training
included progressive
relaxation, imagery,
and controlled
breathing

Eligible if
scored ≥ 10 on
the BDI and met
DSM-IV criteria
for major or
minor
depression
based on the
DISH

Results

Females 50%
Minorities 19%
Burgess18
(1987)

RCT

N = 180

2 arms

Post acute MI

13
months

Females 14%
Minorities not
reported

ZDS

A mean of 6.32 CT
visits per patient,
social support,
facilitation of job
return

Table 2.2: (Continued)
First
author
(year)
Cowan19, 20
(2001)

Design,
Sample
follow-up
time
N = 133
RCT
2 arms

Sudden cardiac
death survivors

Measurement
of depression
SCR-90:
Depression
subscale

3 months
Black21
(1998)

RCT
2 arms

23
6 months

Females 27%
Minorities 10%
N = 60
Recently
hospitalized for
angina, MI,
angioplasty, or
CABG
Eligible if
scored as
distressed
Females 12%
Minorities not
reported

SCR-90:
Depression
subscale

Treatment

11 sessions of
combined CT,
biofeedback, and
health education,
administered
biweekly for six
weeks
1 to 7 weekly
sessions with a
psychologist
including: relaxation
training, stress
management,
reduction of risk
factors, efforts to
improve adherence,
and CT intervention;
antidepressants if
necessary

Control

Results

90 minute health
education class

Depressive symptoms
decreased in the
treatment group when
compared to the
control group

Cardiac
rehabilitation with
monitored
exercise 1-3
times per week,
for 8 weeks, daily
home exercise.
Education on
stress
management,
support group
meeting with
spouses,
individual nutrition
counseling

The CT group had
significant reductions
in depressive
symptoms compared
to the control group
(-5.2 vs. -0.2, p < .034)

Table 2.2: (Continued)
First
author
(year)
Frizelle22
(2004)

Design,
Sample
follow-up
time
N = 22
RCT
2 arms

Measurement
of depression
HADS

Patients with
ICD’s

3 months
Females not
reported
Minorities not
reported
24

Kohn23
(2000)

RCT

N = 49

2 arms

Post-ICD
implantation

9 months
Females 35%
African
American 8%

BDI version II;
4 biological
measures of
depression:
sexual
functioning,
appetite,
weight
change, and
sleep patterns

Treatment

Control

Group-based
Wait list
therapy, six
sessions, 1 hour
each: home-based
exercise, education,
relaxation, behavioral
goal setting,
education on
identifying and
challenging negative
thoughts
9 sessions ranging
Usual care
from 15-90 minutes,
sessions included
psycho-education on:
anxieties about ICD,
avoidance behavior,
fear of shocks, stress
management, work
and social activities,
distorted cognitions

Results

The treatment group
experienced
decreases in
depressive symptoms
compared to the
control group
(-4.25 vs. -0.2, p =
.001)

The CT group had
lower levels of
depressive symptoms
at follow-up compared
to the control group
(6.9 vs. 15, p = .037),
but depressive
symptoms were not
measured at baseline

Table 2.2: (Continued)
First
author
(year)
Lewin24
(2007)

25

Design,
Sample
follow-up
time
Clustered N = 192
RCT
Patients
undergoing ICD
2 arms
implantation
6 months
8 implantation
centers in the
UK were
randomized to
intervention or
control
Females 20%
Minorities 3%

Measurement
of depression
HADSDepression
subscale

Treatment

Control

Results

Intervention
consisted of 2
booklets for patients,
1 booklet for family, a
goal-setting diary
and a relaxation
tape. The first
booklet targeted
fears prior to ICD
implantation. The
second booklet
consisted of a selfhelp CT program.
The intervention was
delivered by
healthcare staff that
underwent a half day
of training.

Usual care and
contact by a
study facilitator to
discuss
postoperative
progress

The intervention group
experienced a greater
reduction in the
proportion of patients
with depression at six
months compared to
the control group (13.2% vs. -2.1%, p
value not reported)

Table 2.2: (Continued)
First
author
(year)
Kostis25
(1994)

Design,
Sample
follow-up
time
N = 20
RCT
3 arms
3 months

Patients with
congestive
heart failure
Female 30%
Minorities not
reported

Measurement
of depression
BDI

26

Treatment

Control

12 weeks of exercise
training at a cardiac
rehab facility for 1 hr
3 times per week;
weekly meetings with
a dietician; groupbased CT
intervention: twice
weekly for 60-90
minutes (relaxation,
positive imagery,
appraisal of negative
cognitions)

1. Lanoxin titrated
to achieve levels
between 0.8-2.0
ng/mL
2. Placebo

Results

There was a 52%
decrease in BDI
scores in the
intervention group
compared to a 15%
and 25% increase in
the control groups at
follow up (p = .04)

Table 2.2: (Continued)
First
author
(year)
26

Lincoln
(2003)

Design,
follow-up
time

Sample

RCT

N = 123

3 arms

1 to 6 months
post-stroke

Measurement
of depression

BDI
WDI

6 months
Eligible if
scored as
depressed
27

Female 49%
Minorities not
reported

27

Lustman
(1998)

RCT

N = 51

2 arms

Type II diabetes
and major
depression

6 months

Females 60%
Minorities 19%

DIS
BDI

Treatment

Stroke
Ten 1-hour sessions
over 3 months,
tailored CT
intervention:
education, task
assignment, activity
scheduling,
identification and
modification of
inaccurate thoughts

Diabetes
1 hour per week of
individual CT for 10
weeks, strategies
included: behavioral
strategies, problem
solving, and
cognitive techniques
to change cognitive
errors

Control

Results

1. No intervention
2. Attention
placebo: Ten 1 hr
visits over 3
months

No significant
differences between
groups in depression
scores

Attention placebo:
1 hour, biweekly,
individual
sessions with a
diabetes educator

The CT group had a
higher rate of
remission from
depression compared
to the control group
(58.3% vs. 25.9%, p =
.03)

Table 2.2: (Continued)
First
author
(year)
Snoek28
(2008)

Design,
Sample
follow-up
time
N = 86
RCT
2 arms
12
months

Measurement
of depression
CES-D

Adults with
poorly
controlled type I
diabetes
Females 58%
Minorities: not
reported

28

Henry29
(1997)

RCT

N = 19

2 arms

Type II
Diabetes

BDI

7 weeks
Females 53%
Minorities not
reported

Ismail30
(2008)

RCT

N = 344

3 arms

Adults with
poorly
controlled type I
diabetes

12
months

PHQ-9

Treatment

Control

Results

6 weekly group
sessions of CT
delivered by a
diabetes nurse
educator and a
psychologist.
Sessions focused on
cognitive
restructuring,
behavior change and
stress management
Six sessions of 1.5
hours: progressive
muscle relaxation,
cognitive coping
training (such as
identifying and
modifying negative
thoughts), problemsolving skills,
homework
assignments
1. CT plus
motivational
enhancement: 4
individual sessions of
motivational
enhancement

Blood glucose
awareness
training focused
on symptom
management and
diabetes
education,
delivered by a
diabetes nurse
educator and a
psychologist
Wait-list

There were no
differences between
groups with regard to
change in depressive
symptoms over time

Usual care

Neither group
experienced an
improvement in
depressive symptoms
compared to usual
care

Depressive symptoms
decreased across time
in both groups; there
was no difference
between groups

Table 2.2: (Continued)
First
author
(year)

Design,
follow-up
time

Sample

Females 60%
Minorities 20%

Measurement
of depression

Treatment

Control

Results

29

therapy (see below)
and 8 sessions of CT
delivered over 6
months by trained
diabetes nurses
2. Motivational
enhancement: 4
individual sessions
delivered over 2
months by a diabetes
nurse. Sessions
focused on
assessment of
readiness to change,
diabetes behavior
modification, and
problem solving

BDI: Beck Depression Inventory version I; CABG: Coronary bypass grasft surgery; CT: Cognitive Therapy; DIS: Diagnostic Interview
Schedule; DISH: Depression Interview and Structured Hamilton; HADS: Hospital Anxiety & Depression Scale; HRSD: Hamilton
Rating Scale for Depression; PHQ-9: Patient Health Questionnaire; SCR-90: Symptom Checklist 90 Revised; WDI: Wakefield
Depression Inventory; ZDS: Zung Depression Scale

CHAPTER THREE:
Living with Depressive Symptoms: Patients with Heart Failure
1. Introduction
Heart failure (HF) is a chronic syndrome that affects 5.8 million people in the
United States1 and is the most common cause of hospitalization in elderly adults.2 Major
depressive disorder is common in hospitalized patients with HF. One-third of
hospitalized patients with HF suffer from major depression, and 40% of these are still
depressed one year later.3 According to the American Psychiatric Association, a major
depressive episode consists of five or more symptoms which are present most of the
day for at least two weeks. One of these symptoms must be depressed mood or loss of
interest in usual activities, and the symptoms must cause significant distress in social,
occupational, or other areas of functioning.4
Individuals can experience significant depressive symptoms without a diagnosis
of major depressive disorder.5 Sometimes called subthreshold depression, depressive
symptoms include depressed mood, guilt, hopelessness, low self-esteem, fatigue, sleep
disturbances, appetite change, and inability to concentrate.6 Researchers have proposed
that depressive symptoms lie within a continuum of depressive illness severity, which
ranges from mild depressive symptoms to a diagnosis of major depressive disorder.7 It is
estimated that up to 48% of outpatients with HF experience clinically significant levels of
depressive symptoms.8 The presence of depressive symptoms has important clinical
consequences for patients with HF. Patients with HF who have depressive symptoms
experience reduced health-related quality of life and an increased risk of
rehospitalization and mortality.8,9
Although researchers have examined the predictors and outcomes of depressive
symptoms in patients with HF, none have described the experience of living with
depressive symptoms. Qualitative research can help researchers and clinicians
understand a phenomenon from the patient’s point of view and guide the development of
future interventions. The purpose of this qualitative study was to describe the experience
of living with depressive symptoms in persons with HF. The primary research question
was: How do persons with HF describe their depressive symptoms? Secondary research
questions included: What factors influence depressive symptoms? What are strategies
that persons with HF use to manage depressive symptoms?
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2. Methods
2.1. Qualitative description
This investigation was conducted using a qualitative descriptive design.
Qualitative description involves low-inference interpretation and is often the first step in
exploration of a phenomenon. The result is a descriptive summary of the experience in
everyday language.10 This topic is particularly suited for qualitative description because
little is known about how patients with heart failure describe their depressive symptoms.
2.2. Participants
The study was nested in a clinical trial of biofeedback and cognitive therapy in
patients with HF. Institutional Review Board approval was obtained prior to recruitment.
Patients were eligible to participate if they were diagnosed with chronic HF, stable on
cardiac medications, had no coexisting terminal illness, and had not had a stroke or
myocardial infarction within three months.
Purposive sampling was used to select ten outpatients who had a self-reported
history of past or current depression, or were experiencing a clinically significant level of
depressive symptoms, defined as a score of 14 or greater on the Beck Depression
Inventory-II11 upon enrollment in the trial (Table 3.1). Purposive sampling ensured equal
numbers of men and women and equal representation from the intervention and control
groups. The intervention group received six weeks of biofeedback training and cognitive
therapy from a psychiatric nurse practitioner, while the control group received six weeks
of attention placebo, which consisted of self-selected relaxation exercises delivered by a
psychiatric nurse practitioner.
2.3. Data collection
One-time, semi-structured interviews were conducted in the participants’ homes
after the intervention or placebo portion of the trial was completed. Results from two
initial interviews found that patients had difficulty answering direct questions about
symptoms of depression. Therefore, interviews began with questions regarding recent
stressful events to elucidate depressive symptoms. Questions explored the participant’s
symptoms that occurred during the stressful event. Each participant was asked to share
techniques that they used to prevent or cope with depressive symptoms. Interviews
lasted between 30 and 60 minutes and were audio taped. Participants were reimbursed
$30 for their time.
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2.4. Data analysis
An inductive approach to content analysis was used in this study. Interviews
were transcribed verbatim and transcriptions compared to the taped interviews to assure
accuracy. A codebook was developed to assist in the analysis. The codebook contained
a priori codes based on a literature review, as well as codes that emerged from the data.
We used Atlas ti (version 5.0) to code the data. Each interview was read, re-read, and
coded by the primary author. The transcripts were compared to ensure that coding was
consistent throughout, and codes were first sorted into categories and then into larger
themes. Data displays that depicted the frequencies of the codes were developed to
assist in the reduction of the coded data into categories.12 The abbreviated data display
for factors influencing depressive symptoms is provided in Table 3.2 as an example of
the data displays used for data reduction.
2.5. Trustworthiness and credibility
To establish trustworthiness and credibility, we used three procedures
recommended by Creswell.13 First, we clarified bias prior to data collection by bracketing
assumptions. Bracketing assumptions consists of writing down personal assumptions
about the phenomenon; this process allows the researcher to collect data with as
unbiased a viewpoint as possible. Second, the coauthors met frequently throughout data
analysis to verify the coding accurately reflected the content of the interviews. Third, the
research results were returned to three participants to verify accuracy of the findings.
3. Results
3.1. Depressive symptoms
The participants’ descriptions of depressive symptoms were similar to symptoms
of depression as defined by the Diagnostic and Statistical Manual-IV-TR criteria.4 The
participants described emotional symptoms of sadness, irritability, tearfulness, and
anxiety. The participants also experienced somatic symptoms that they attributed to
depression, including lack of energy, changes in appetite, sleep disturbances, and
difficulty concentrating. Finally, the participants described experiencing negative thinking
and cognitive distortions.
3.1.1. Emotional symptoms
Eight of the ten participants described sadness as part of their experience with
depression. The participants used the terms “terrible sadness,” “depressed,” “moody,”
“bad blue mood,” and “upset” to describe their mood. Six of the participants stated that
tearfulness was a frequent symptom. One participant cried during the interview, stating:
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“It’s just I’m sad. And I think it’s just because there’s a lot of sad stuff. It’s just
been really hard.”
Half of the participants complained of feeling irritable. They expressed feelings of
aggravation, frustration, and anger. In many cases irritability resulted in strained
relationships with children or spouses. As one participant said, “Sometimes I could just
scream and one day I did, several times I have, about them not cleaning.”
In addition to sadness and irritability, feelings of anxiety were described by nine
participants. The participants used “tense,” “tight,” “shaky,” “nervousness,” “worry,” and
“fear” to describe their anxiety. One participant shared:
“At night I start thinking about it, the consequences of what could happen and
what couldn’t and what would come out good, and I just, just get in a knot again.”
3.1.2. Somatic symptoms
Seven participants described somatic symptoms attributed to depression that
included changes in appetite, sleep disturbances, and lack of energy. Only one patient
described an increase in appetite while three others described a loss of appetite. Three
of the participants described sleep disturbances. One participant in particular spent
much of her time sleeping. At her request, the interview took place in her bedroom, while
she sat in bed. She said, “Sometimes I just come in the room, shut the door and go to,
and just go to sleep, just lay here.” Only three participants complained of a lack of
energy.
3.1.3. Negative thinking
All ten participants described negative thinking, or self-critical thoughts.14
Participants described thoughts such as, “I can’t justify my existence,” “I have nothing to
offer anymore,” and “I’m a failure.” The participants stated that the negative thoughts
reinforced their depressed mood. As one participant shared:
“Sometimes it gets me down because I start thinking about other things... You
know, it just kind of moves up to keep going up the ladder.”
Participants described cognitive distortions that accompanied negative thinking.
Magnification is a cognitive distortion in which a person inflates the magnitude of the
problem.15 For example, when one participant underwent surgery, she could only think
about the possibility of death:
“Am I going to come out of this, am I going to die, you know is this my last time,
or I’m going to die in there on the operating table.”
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Another frequently mentioned distortion was dwelling. Dwelling is defined as long,
uninterrupted series of depressive thoughts that worsen depressive symptoms.15, 16
When asked what advice she would give to someone in her situation, one participant
answered:
“I think I would tell them you know from my experience, the more you dwell on it,
the worse off you get.”
3.2. Stressors
Participants described stressors that worsened their depressive symptoms. The
stressful experiences that the participants lived with included financial difficulties, family
problems, health issues, and loss.
3.2.1. Financial difficulties
Seven participants described financial difficulties, including bankruptcy, living on
a fixed income, and being disabled. One participant said that finances were the primary
contributor to her depressed mood:
“I think the main thing well that, that upsets me is finances. If my finances get to
the point where I get to a week before payday and I don’t have any money, then I get
very stressed and I think that stresses everybody. But I think it especially stresses me.”
3.2.2. Family problems
Nine participants talked about stressful situations in their families. Problems that
the participants dealt with ranged from children who were incarcerated, to grandchildren
who were having problems, to alcoholism and arguments among family members. The
participants described feeling worried about family situations and saddened or irritated
by conflict. One participant felt depressed because he was estranged from his only child:
“Well I felt sad there for a long time because my daughter, I wanted to be in contact with
her and I felt hurt... I want to be somebody my daughter can depend on me being there
when she needs me.”
3.2.3. Health issues
Interestingly, only five of the participants mentioned HF as influencing depressive
symptoms. Three participants stated that depressive symptoms were present prior to the
development of HF. One participant said that having HF did not make her depressed.
Instead, “it’s just something else for me to be depressed about.” The majority of
participants described other health conditions as being stressful and contributing to
depressive symptoms. Participants described dealing with cancer, diabetes, arthritis,
and chronic pain.

34

3.2.4. Loss
The participants described numerous losses that worsened their depressive
symptoms. Four of the participants described the death of a son or daughter. One
participant had experienced the death of two children. Although some of these deaths
had occurred years ago, it was clear that the participants still felt the effects of the loss.
Complicating the bereavement process for these participants was the fact that all of the
deaths were sudden. One participant said:
“Well of course you know it’s been in 2003 when my daughter died suddenly and I still
haven’t gotten over that and of course at night sometimes I cry over that.”
Other participants did not discuss the loss of a loved one, but they experienced
other losses. One participant described the loss associated with not being able to work:
“I used to get really depressed. I can’t work anymore; what am I going to? I mean, it
really bothered me at first.”
3.3. Strategies for managing depressive symptoms
The overarching strategy described by the participants was “taking my mind off of
it.” Four types of strategies were used by participants to take their minds off of
depressive symptoms: activities, distraction, social support, and medical intervention.
3.3.1. Activities
Exercise was mentioned by nine participants as being an important method of
reducing depressive symptoms. The most commonly mentioned exercise was walking.
The participants repeatedly said that walking made them feel better, and that any
amount of exercise was better than just “sitting around.” One participant stated:
“I’ve started walking. It’s fun. I put my, I take my radio and listen to my music and
it makes me feel good because I kind of walk and do a little dance while I’m walking and
so, so it has made me feel good when I was walking.”
In response to the question, “What are some of the things that help you feel
better when you feel down,” nine participants mentioned reading. The participants who
had difficulty reading would listen to books on tape instead. As one participant said,
“Rather than sit here and think about the bad things you know, I can get me a book to
listen to.” For most participants, reading allowed them to “take their mind off things” and
focus on something other than the depressive symptoms.
Being active, or “staying busy,” was mentioned by six participants as a behavioral
tactic that kept them from thinking about depressive symptoms. Participants used a
variety of activities to stay busy, such as bird watching, crocheting, and watching
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television. The simple act of getting involved in an activity helped relieve the participant’s
depressive symptoms.
“Sometimes I like to do crafts. I like to work crosswords and do Sudoku. Other
times that just gets my mind off things and just concentrating on that one thing.”
3.3.2. Distraction
For these participants, distraction is defined as the ability to redirect one’s
internal focus away from negative thoughts or emotions. For seven participants,
spirituality or religiosity was an important method of distraction. Participants received
relief by praying, attending church, and reading scripture. One participant quoted Biblical
scriptures several times. He said, “When we fill our mind and our heart with the
scriptures, that’s something that we can depend on.”
A central component of spirituality was a relationship with God. One participant
described God as “my other best friend.” Another participant said:
“I feel I have a great relationship to God because I talk to him about a lot of
things and when I do, I feel better. I feel that a burden has been lifted from me; not all
the time right away but it’s been, you know it’s been lifted.”
When asked: “If you were talking to someone like you who felt depressed or
down, what advice would you give them?” nine of the ten participants discussed positive
thinking. Positive thinking is a central component of the cognitive therapy intervention
which five of the participants had received. However, four of the five control group
participants also discussed positive thinking. As one control group participant said:
“The main thing I think that I’ve found is trying to keep my mind off of things that
make me sad. If I find myself drifting that way, well then I know right away I’ve got to
think of two positives. Because that’s a negative. And like I said, when you’ve got a
negative, you’ve got to come up with two positive things to replace that.”
Instead of dwelling on negative thoughts, the participants redirected their
thoughts towards the positive. One participant focused on the future:
“Think about the future. Think about the future; don’t dwell on the past, there’s
nothing you can do. It’s happened; it is depressing. You know that your life has changed;
it’s changed your life completely. But think about the positive you know, life goes on.”
Others focused their thoughts on affirmations. One participant read his
affirmations out loud:
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“My heart may be sick, but my mind and soul are strong and healthy. My
problems are an opportunity for me to grow as a person. I’m a person of value even if I
have heart failure, back trouble, knees and shoulder, and I’m old.”
Additional examples of affirmations included: “I’m alive, I’m thankful for that, I’m
alive,” “Things are going to get better, going to get better,” and “I might not be able to do
the things I used to do but there’s new things I can do.”
3.3.3. Social support
All ten participants stated that social support was an important factor in reducing
depressive symptoms. Family and friends provided emotional, physical, and financial
support. The married participants all provided positive descriptions of their marriages. As
one participant said:
“I do appreciate that lady [indicating wife] over there. The Lord drawed us
together and we were married after getting out of the service…Yes we celebrated our
50th about 3 years ago. And pretty soon we’ll come up with number 54.”
3.3.4. Medical intervention
Seven of the participants (five females and two males) were taking
antidepressants at the time of the interview, yet only four participants—all women—
mentioned antidepressants as a strategy for managing depressive symptoms. One
participant described how antidepressants helped her enjoy sunlight again:
“I used to hate days like today where it was sunny. Like I couldn’t stand to be in
the sun and ever since I’ve been on antidepressants, I enjoy sunshine.”
4. Discussion
4.1. Discussion of findings
The participants in this study described emotional and somatic symptoms of
depression, as well as negative thoughts that worsened their mood. Stressors such as
financial difficulties, family problems, and health conditions exacerbated the depressive
symptoms. Individuals described “taking their mind off” depressive symptoms through
activities, distraction, social support, and medical intervention.
The depressive symptoms experienced by the participants were similar to those
experienced by the general population with depressive symptoms. The majority of the
sample experienced a depressed mood. This is particularly interesting since seven
participants were currently receiving antidepressant therapy. The finding that our
participants experienced significant emotional symptoms contrasts with results from a
prior study in which a sample of outpatients with HF and major depression living in
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Germany had fewer emotional symptoms of depression, as measured by the Patient
Health Questionnaire-9 (PHQ), when compared to patients with major depression who
did not have HF.17 It is possible that the PHQ did not effectively capture the emotional
symptoms that are experienced by patients with chronic HF. The participants in our
study may have also been more likely to divulge emotional symptoms in their home
environment, as opposed to a clinic or research setting.
Few somatic symptoms of depression were mentioned by participants. It is
possible that the participants attributed somatic symptoms to HF rather than depression.
Several common symptoms of HF, such as fatigue, anorexia, and sleep disturbances,
overlap with symptoms of depression. This symptom overlap may contribute to the
participants’ difficulty in recognizing somatic symptoms of depression.17 In addition,
clinicians may also attribute somatic symptoms to HF instead of depression. This lack of
recognition of the somatic symptoms of depression could contribute to the low treatment
rates of depression in persons with HF,3 as well as under-treatment which results in
individuals not receiving therapeutic doses of antidepressants.
An important finding of this study was that negative thinking was common and
had a detrimental impact on the participants’ mood. The presence of negative thoughts
has been described as a characteristic of major depression.15 However, this was the first
to describe negative thinking as important in patients with HF who have depressive
symptoms. The participants experienced cognitive distortions that maintained their
negative thought processes. Researchers have found that magnification is an
independent predictor of depressive symptoms in the elderly.16 In addition, depressed
patients who “dwell” on negative thoughts experience a worsened mood and are less
able to problem solve.18
The participants described a variety of stressors that worsened their depressive
symptoms. This finding is consistent with results from other qualitative studies on living
with HF. Investigators have found that patients with HF experience physical, emotional,
and social turmoil in their everyday lives19, as well as multiple personal struggles and
losses.20,21 In combination, these studies demonstrate that having a diagnosis of HF is
only one stressor in a life full of difficulties.
Many clinicians assume that patients with HF are depressed because they have
been diagnosed with HF. However, only half of the participants mentioned HF as
influencing depressive symptoms. Future qualitative research should explore whether
patients with HF attribute depressive symptoms to HF. For three participants, depression
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was something that they struggled with for years prior to the onset of HF. Pre-existing
depression has been demonstrated to be an independent risk factor for development of
HF.22,23 Thus, the long history of depression may have increased the risk of developing
HF in these participants.
Of particular interest are the multiple strategies described to counteract
depressive symptoms. The overarching strategy was “taking my mind off of it.”
Participants used activities, distraction, social support, and medical intervention to
alleviate their symptoms. Activity in the form of exercise appears to be as effective as
antidepressants for the treatment of depression in the elderly.24 Results from several
small trials have shown that exercise improves depressive symptoms in patients with
HF.25,26
The participants’ use of social support to alleviate depressive symptoms is
supported by the literature. Results from one study demonstrated that an increase in
perceived social support was the only factor that predicted faster remission from
depression in hospitalized patients with HF.3 In contrast, poor social support, defined as
living alone, independently predicts the development of depressive symptoms in HF
patients27, while single marital status also predicts depressive symptoms in patients with
HF.28
For most of the participants, spirituality was an important method of managing
depressive symptoms. Researchers have demonstrated an inverse relationship between
spiritual well-being and depressive symptoms in patients with chronic HF.29 In addition,
researchers have demonstrated that older patients with HF who are involved in religious
activities remit faster from depression than non-religious patients.30
The participants used positive thinking more than any other strategy to manage
their depressive symptoms. They also expressed that affirmations were an important
method of reducing negative thoughts. The evidence to support positive thinking and
affirmations as effective strategies is found in cognitive therapy, which is based on the
Cognitive Model of depression. The Cognitive Model proposes that redirecting negative
cognitive processes into positive ones can improve the symptoms of depression.31 The
use of cognitive strategies was not surprising for the five participants who received
cognitive therapy in the parent study. However, four of the five control group participants
also discussed positive thinking as a strategy for managing depressive symptoms.
Although the majority of the participants were taking antidepressants, few
mentioned medications as a method to manage depressive symptoms. It is possible that

39

participants did not view their depressive symptoms as a medical condition. Thus they
may not have considered antidepressants as a strategy for managing depressive
symptoms. Selective serotonin reuptake inhibitors (SSRIs) are often prescribed for
depression in patients with HF because of the lack of cardiac side effects.32 Currently,
there is little evidence regarding the efficacy of SSRIs for treating depression in patients
who have HF. However, a large randomized, controlled trial is currently underway.33
4.2. Limitations
Because of the heterogeneity of depressive symptoms experienced by
participants it may be necessary to obtain more viewpoints to fully understand the
experience of living with depressive symptoms in persons with HF. Similarly, only one
interview was conducted with each participant. Additional interviews may have revealed
other depressive symptoms and coping strategies or provided additional insight into the
connection between HF and depressive symptoms. This study included participants who
experienced a cognitive therapy intervention which may have influenced participant
experiences. This strategy can also be considered a strength because it included
patients with a broad range of perspectives.
5. Conclusion
The results of this study have important implications for clinicians and
researchers who work with patients with HF. Given the negative outcomes associated
with depressive symptoms, clinicians must assess hospitalized patients with HF for the
presence of depressive symptoms as well as stressors that might exacerbate depressive
symptoms. It also is important for clinicians and researchers to note that depression in
patients with HF may benefit from the same interventions that are effective for treating
depression in the general population. Participants in this study managed depressive
symptoms through the use of activities, distraction, and social support. These strategies
are worthy of development and testing among patients with HF in the acute care arena.
This study is the first to identify that negative thinking may be an important
component of depressive symptoms in patients with HF. By targeting negative thinking,
clinicians may be able to reduce depressive symptoms in patient with HF. Clinicians can
teach hospitalized patients with HF to recognize negative thoughts and replace them
with positive thoughts and affirmations. For example, an acute care nurse could ask a
hospitalized patient with HF, “What kinds of thoughts are you experiencing right now?”
After assessing for the presence of negative thoughts, the nurse can teach the patient
how to replace negative thoughts with positive ones. Clinicians also may help alleviate
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hospitalized patients’ depressive symptoms by assessing their spiritual well-being and
referring patients with needs to appropriate spiritual care. Encouraging the patient to
engage in activities such as ambulating or reading while they are hospitalized may also
reduce depressive symptoms. Finally, helping patients’ significant others provide
enhanced social support may be an important method for reducing depressive
symptoms in patients with HF.
Clinicians can no longer ignore the fact that patients with HF experience levels of
depressive symptoms that reduce quality of life and increase the risk for mortality. This
study is the first description of the experience of living with depressive symptoms in
patients with HF. Clinicians can use the results from this study to gain understanding of
the patients’ perspective of living with depressive symptoms. Researchers can use the
results to develop and test interventions to reduce depressive symptoms.
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Table 3.1: Participant characteristics
Characteristic

Percentage or Mean ±
standard deviation
50%

Female
Age
Minority

62.5 ± 13.2
Range: 37-81 years
20%

Married

70%

NYHA Class I
Class II
Class III
Class IV
Some college education or greater

10%
20%
60%
10%
70%

Employed

20%

Beck Depression Inventory –II score

18.9 ± 11.8
Range: 7 - 40
Antidepressant use
70%
NYHA = New York Heart Association functional classification
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Table 3.2: Data display for factors influencing depressive symptoms
Code
Family
problems

Frequency Example Quote
9/10
“Kids and grandkids…something is always going on in
their lives. And at least one of them always has a
problem of some kind to deal with.”

Loss

9/10

Finances

7/10

Health
problems

8/10

Heart
failure

5/10

History of
depression

3/10

“Even though it’s been 11 years since my daughter died,
I have days where I think about her a lot. I mean it never
gets easy.”
“We just went through a bankruptcy. And that was not
easy. I don’t like things like that but there was nothing we
could do.”
“I’ve been having a lot of problems with the back, a lot of
pain and so on. I’ve had all kinds of treatments and
nothing works.”
“The only thing that stresses me really is I want to be
able to breathe better so that I can do more around the
house.”
“See, I’m a person who’s fought depression all of my life,
I mean even when I was a child.”
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CHAPTER FOUR:
Measurement of Negative Thinking in Patients with Heart Failure:
A Critical Review and Analysis
Synopsis
1. Introduction
The purpose of this paper is to present a critical review of the measurement of
negative thinking to provide direction for the measurement of negative thinking in
patients with heart failure (HF). Negative thinking can be defined as depressive
cognitions about the self, world, future, and withdrawal from others.1 Negative thinking is
a cognitive process that is automatic and persistent;2 it originates in childhood and
dominates the perceptions of the depressed individual.3 Examples of negative thoughts
include, “I’m worthless,” “Everything I do is a failure,” and “Nothing’s ever going to work
out for me.”1 Although the content of negative thoughts is irrational, these thoughts are
believable to the person experiencing them.2
Negative thinking has several adverse consequences in the general population.
First, negative thinking is a risk factor for depressive symptoms,4, 5 as well as an
independent predictor of the later development of depression among women.6, 7 Second,
negative thinking exacerbates and maintains depressive symptoms, which contributes to
a downward spiral of depressive symptoms that may end in major depressive disorder.2,
8

Third, negative thinking independently predicts a worsened response to treatment for

depression, even after controlling for history of depression and depressive symptoms at
baseline.9
Depression is a significant clinical problem in patients with HF. Twenty percent of
outpatients with HF suffer from major depressive disorder,10 and up to 48% of
outpatients experience clinically significant depressive symptoms.11 Patients with HF
who are depressed have a two-fold greater risk of death or hospitalization compared to
patients who are not depressed.12
In a recent qualitative study, patients with HF who had depressive symptoms
described experiencing negative thinking which exacerbated their depressed mood.13
This finding is consistent with Beck’s Cognitive Model of depression, which proposes
that negative thinking influences the emotional, behavioral, and somatic symptoms of
depression.14 The patients in the qualitative study who experienced depressive
symptoms stated that positive thinking was a strategy they used to manage depressive
symptoms.13 Cognitive Therapy, a treatment for depression which re-directs negative
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thoughts into positive ones, may be an effective treatment for depression in patients with
HF.15 In order to test the effectiveness of Cognitive Therapy as a treatment for
depressive symptoms in patients with HF, researchers need a valid and reliable
measure of negative thinking in this population.
Therefore, the objectives of this paper were to provide an overview of the state of
measurement of negative thinking, analyze three existing measures of negative thinking,
and make recommendations for new directions in the measurement of negative thinking
in patients with HF.
2. Overview of the state of measurement of negative thinking
Negative thinking was first defined in 1967 by Beck, a psychiatrist, as the
cognitive triad: negative thoughts about the self, world, and future.2 Since then,
researchers have suggested a fourth type: negative thoughts about interpersonal
relationships or withdrawal from others.1
Endorsement questionnaires are the most common method of measuring
negative thinking.16 These questionnaires contain a list of self-statements or thoughts.
Examples of thoughts on an endorsement questionnaire include, “I wish I were a better
person,” “My life is a mess,” and “It’s just not worth it.”17 Patients are instructed to rate
how often they experience each thought on a Likert scale. Patients usually fill out
endorsement questionnaires retrospectively, although a few instruments call for the
questionnaire to be administered at the same time as a stressful stimulus.
Endorsement questionnaires are cost-effective, easy to administer, and quick to
complete.16 There are only a few disadvantages to using endorsement questionnaires. A
retrospective questionnaire could lead to selective memory bias and socially desirable
responses. It is also possible that endorsement questionnaires do not measure the
frequency of an individual’s actual thought content, but rather the importance of the
thought, the similarity of the thought to other ones they may have experienced, or the
emotional salience of the thought.16, 18 However, researchers have provided evidence
supporting the construct validity and concurrent validity of endorsement questionnaires
for measuring negative thinking.18 As a result, endorsement questionnaires remain the
most widely used method of measuring negative thinking in clinical trials. At least 28
endorsement instruments have been developed to measure negative self-statements.
Only seven of these instruments are used to measure negative thinking specific to
depression. The other instruments measure negative thinking found in conditions such
as anxiety, pain, eating disorders, and panic disorder.16, 18

45

For this paper, three of the most widely used questionnaires that measure
negative thinking in depression were selected for review. These instruments include the
Crandell Cognitions Inventory, the Automatic Thoughts Questionnaire, and the Cognition
Checklist- Depression subscale. The instruments are compared in Table 4.1, and
studies which have examined their psychometric properties are described in Table 4.2.
3. Description of three existing measures of negative thinking
3.1. Crandell Cognitions Inventory
The Crandell Cognitions Inventory (CCI) was developed by Crandell and
LaPointe in 1979 to measure self-statements of depression. The authors initially defined
depressive thoughts as the cognitive triad—negative thoughts about the self, world, and
future. A preliminary version of the CCI was developed with a sample of psychiatric
inpatients, psychiatric outpatients, and persons without a psychiatric illness, and it
contained 81 negative items and 19 non-scored, positive buffer items. Individuals were
asked to rate how frequently they experienced each thought on a scale from 1 (almost
never) to 5 (almost always); the instructions do not give a specific time frame for thought
recall.
The preliminary version of the CCI demonstrated strong evidence of reliability
(Cronbach’s alpha = 0.98) but possible redundancy among the items. The preliminary
version also performed well in discriminating between the three groups; however, the
authors felt that the scale was too lengthy to be clinically useful.1
In 1986, Crandell and Chambless1 revised the CCI with a sample of depressed
psychiatric patients, non-depressed psychiatric patients, and normal controls. Patients
were grouped on the basis of the following: Hamilton Rating Scale scores for
depression, Maudsley Personality Inventory scores, whether or not the patient was
receiving psychological treatment for depression, and whether or not patients had a
clinical diagnosis of depression based on the Research Diagnostic Criteria.
The final version of the CCI consisted of 45 items—34 negative self-statements
and 11 non-scored positive buffer statements. The authors intended the CCI to have
three dimensions: negative views of the self, world, and future, but factor loadings
revealed four dimensions: self-rated inferiority (negative view of the self), helplessness
(negative view of the world), hopelessness (negative view of the future), and detachment
(negative view about withdrawal from others).
The authors stated that the item-total correlations provided support for good
internal consistency (exact correlations not reported). The Cronbach’s alpha was 0.95,
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demonstrating evidence of strong internal consistency reliability, but possible
redundancy among items. The sample in which the CCI was initially tested consisted of
mostly male participants. Researchers have since used the CCI to measure negative
thinking in college women and low-income single mothers, providing evidence of internal
consistency of the CCI among women (Cronbach’s alpha = 0.90 and 0.97;
respectively).4, 19
Support for construct validity of the CCI was demonstrated by a strong
correlation with depressive symptoms measured by the Beck Depression Inventory (r =
0.79, p < .001).1 Divergent validity was tested by comparing the CCI scores with a
measurement of IQ. As expected, the authors found a moderately low correlation
between the CCI and the IQ score (r = -0.23, p < .05), supporting divergent validity.
In order to test the construct validity of the CCI among women, Crandell and
Chambless1 investigated the CCI in a sample of 65 outpatients with panic disorder (82%
female), since clinically significant levels of depression are common in this population.
The authors found a strong correlation between the CCI and the Beck Depression
Inventory (r = 0.77, p < .001), lending support for convergent validity of the CCI among
women. Other researchers have also found evidence for convergent validity of the CCI
among women (see Table 4.2).
Finally, Crandell and Chambless1 demonstrated that the final version of the CCI
had strong evidence of concurrent validity. The total score of the CCI correctly predicted
the classification of 92% of the participants among the three groups: depressed
psychiatric patients, non-depressed psychiatric patients, and normal controls.
3.2. Automatic Thoughts Questionnaire
Hollon and Kendall17 developed the ATQ in 1980 to measure the frequency of
negative automatic thoughts in individuals with depression. The authors defined
automatic thoughts as involuntary, stream-of-consciousness cognitions. The items were
developed by asking undergraduate students to recall a depressing event. The students
were asked to record thoughts or self-statements that “popped into their head.” A total of
100 items were generated for further testing.
After developing the initial items, Hollon and Kendall revised and validated the
ATQ with a sample of 348 undergraduate students. Participants were asked to indicate
how frequently, the thought occurred over the last week, on a scale from 1 (not at all) to
5 (all the time). Twenty-six students were classified as having clinically significant
depressive symptoms according to the Beck Depression Inventory. The authors found
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that 30 items discriminated between students with and without depressive symptoms.
These 30 items were included in the final version of the ATQ. Principal components
analysis revealed that the scale contained four dimensions: personal maladjustment and
desire for change, negative self-concept and negative expectations, low self-esteem,
and giving up/helplessness. The authors state that these four dimensions reflect only
two components of Beck’s cognitive triad: negative views of the self and future.
Hollon and Kendall reported good evidence for internal consistency of the ATQ
using split-half (r = 0.97) and Cronbach’s alpha (r = 0.96). Although the strong
Cronbach’s alphas suggest there could be redundancy among the 30 items, item-total
correlations were all significant and ranged from moderate to strong (r = 0.47 - 0.78),
suggesting that the strong Cronbach’s alpha may reflect strong internal consistency
rather than redundancy. Harrell and Ryon20 provided evidence for internal consistency
reliability, but possible redundancy of the ATQ in a sample that included depressed
outpatients and non depressed medical outpatients. Cronbach’s alpha was 0.98 for both
the depressed and the non depressed groups, while the item-total correlations ranged
from 0.56 to 0.91 Wong et al. also provided support for internal consistency of the ATQ
(Cronbach’s alpha = 0.96) among a sample of Chinese patients with chronic physical
illness.21
Hollon and Kendall17 provided support for construct validity of the ATQ. In a
sample of undergraduate students, participants with depressive symptoms had higher
scores on the ATQ when compared to participants without depressive symptoms (79.6
vs. 48.6, p < .001). Further support for the construct validity of the ATQ was found in
moderate to strong correlations (exact correlations not reported) with the Beck
Depression Inventory and the Minnesota Multiphasic Personality Inventory Depression
Scale.
In evaluating divergent validity, Hollon and Kendall17 hypothesized that there
would be a weak correlation between the ATQ and the State-Trait Anxiety Inventory.
Surprisingly, there was a strong correlation (r = 0.79) between the two scales. The
authors suggest that the lack of divergent validity of the ATQ in this sample may have
been due to the small number of participants with depressive symptoms (8%) and the
frequent comorbidity of anxiety and depressive symptoms.
In contrast, Lamberton and Oei22 reported evidence for the divergent validity of
the ATQ in a sample of patients with major depressive disorder. In this study, there was
a strong correlation between the ATQ and the Beck Depression Inventory (r = 0.63), and
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a weak correlation between the ATQ and the Beck Anxiety Inventory (r = 0.17).
Lamberton and Oei suggest that they were able to find support for divergent validity of
the ATQ because their sample contained large numbers of both depressed and anxious
patients.
Although the ATQ was originally developed with undergraduate students, Harrell
and Ryon20 provided evidence for concurrent validity of the ATQ with psychiatric
patients. Participants were divided into three groups: a depressed psychiatric group, a
non-depressed psychiatric group, and a non-depressed medical patient group. Group
assignments were made on the basis of a combination of Beck Depression Inventory
scores, the Minnesota Multiphasic Personality Inventory Depression Scale, and clinician
depression rating scores. The ATQ scores correctly classified 93% of the patients as
depressed psychiatric patients, non-depressed psychiatric patients, or non-depressed
medical patients.
3.3. Cognition Checklist- Depression
Beck, Brown, Steer, Eidelson, and Riskind23 developed the Cognitive Checklist
(CCL) in 1987 to measure the frequency of negative thinking found in depression and
anxiety. The authors defined negative thinking of depression as automatic thoughts,
perceptions, and images that center on negative attitudes toward the self, past and
future. In contrast, negative thinking of anxiety was defined as automatic cognitions
focused on a theme of danger. The authors stated that previous scales, such as the CCI
and ATQ, did not adequately differentiate between cognitions found in depression and
anxiety. Therefore, Beck et al.23 designed a depression subscale (CCL-D) and an
anxiety subscale (CCL-A) that specifically measure cognitions found in depression and
anxiety.
Items for the CCL were derived from collections of automatic thoughts that were
recorded by patients in daily thought diaries during Cognitive Therapy treatment. The
preliminary version of the CCL contained a total of 43 items. In order to revise the scale
and provide evidence of validity, the authors recruited a sample of 618 psychiatric
outpatients. The sample was divided into two subsamples: an index sample and a crossvalidation sample. All of the patients were diagnosed according to a Structured Clinical
Interview. Major depressive disorder was a primary diagnosis in 51% of the index
sample and 46% of the cross-validation sample. Generalized anxiety disorder was a
primary diagnosis in 24% of the index sample and 35.7% of the cross-validation sample.
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Participants were asked to indicate how often each thought occurred to them on
a 5-point scale ranging from 0 (never) to 4 (always) when recalling specific situations
(attending a social occasion, with a friend, working on a project, and experiencing pain
or physical discomfort) and regardless of the situation. No specific time frame was given
for the situation recall. During the revision process, the first 212 participants were also
asked to label the predominant affect (depression or anxiety) they experienced while
thinking each thought. A SPSS Discriminant program was used to determine whether
each item was able to discriminate between patients with a primary diagnosis of
depression versus anxiety. Items which discriminated between depressed and anxious
patients were included in the CCL-D subscale only if patients labeled the thought as
depressing. The final CCL-D subscale contained 14 items, and the CCL-A subscale
contained 12 items. The authors conducted factor analysis with the entire CCL scale and
found evidence for two dimensions: negative thinking of depression and negative
thinking of anxiety. The items on the CCL-D subscale fit into only three of the five
recalled situations: attending a social occasion, with a friend, and regardless of the
situation.
Results from the cross-validation sample showed good evidence for internal
consistency. Cronbach’s alpha for the CCL-D was 0.92, and the average item-total
correlation was strong (r = 0.65).23 Steer et al.24 also found good evidence for the
internal consistency of the CCL- D in a large study that tested the psychometric
properties of the CCL-D among undergraduate students and psychiatric outpatients
(Cronbach’s alpha = 0.90 – 0.93).
Beck et al.23 provided evidence of construct validity for CCL-D. Although the
CCL-D was correlated with both depressive symptoms and anxiety symptoms as
measured by the Hamilton Psychiatric Rating Scales, the CCL-D was more strongly
correlated with the depression scale (r = .62) than with the anxiety scale (r = .37). This
lends support for both convergent and divergent validity.
Results from a study by Steer et al.24 provide additional evidence for convergent
and divergent validity of the CCL-D. The sample consisted of psychiatric outpatients
diagnosed with a primary mood disorder (51.6%), a primary anxiety disorder (35.3%), or
other psychiatric disorders (13.1%) The authors also tested the CCL-D with a sample of
undergraduate students. The results demonstrated that the CCL-D was strongly
correlated with the Beck Depression Inventory among both psychiatric outpatients (r =
.66, p < .001) and undergraduate students (r = .58, p < .001). In contrast, the CCL-D had
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a weaker correlation with the Beck Anxiety Inventory among both psychiatric outpatients
(r = .32, p < .001) and undergraduate students (r = .37, p < .001).
The CCL-D has less evidence for divergent validity among patients who are
hospitalized for a chronic physical illness. Clark, Cook, and Snow25 reported that the
CCL-D demonstrated divergent validity among psychiatric inpatients; however, when the
CCL-D was administered to patients who were hospitalized with a chronic physical
illness, the CCL-D was strongly correlated with both depression and anxiety subscales
of the Hospital Anxiety and Depression Scale (r = .60 and .69, p < .001). This indicates
that the CCL-D may be less likely to discriminate between negative thinking of anxiety
and depression in patients with a chronic physical illness.25
In testing concurrent validity of the CCL, Beck et al.23 divided patients into a
depressed group and an anxious group based on a Structured Clinical Interview and
Hamilton Anxiety and Depression Scale scores. Patients were included in the depressed
group if they had both a primary diagnosis of depression and a Hamilton Depression
Scale score at least 0.5 standard deviation higher than the Hamilton Anxiety Scale
score. Similarly, patients were included in the anxious group if their primary diagnosis
was anxiety and their Hamilton Anxiety Scale score was at least 0.5 standard deviation
higher than the Hamilton Depression Scale score. Using a discriminant classification
analysis, the CCL was able to correctly classify 83% of the depressed patients and 79%
of the anxious patients.
Researchers have used the CCL-D to compare levels of negative thinking
between depressed psychiatric patients and depressed physically ill patients. Clark,
Cooke, and Snow25 classified patients as depressed according to the Structured Clinical
Interview for the DSM-III. The mean score of the CCL-D was substantially lower in the
depressed physically ill group compared to the depressed psychiatric group (12.22 vs.
24.24, p < 0.05). Martens et al.26 also found a low level of negative thinking among
patients who had recently experienced a myocardial infarction and were classified as
depressed according to a Structured Clinical Interview. The depressed post-myocardial
infarction patients had significantly lower scores on the CCL-D compared to psychiatric
outpatients (28 vs. 34.9, p = 0.01), after adjusting for age, sex, educational level, and
marital status. The results from these studies raise the possibility that depressed
patients who have recently experienced a myocardial infarction have lower levels of
negative thinking than depressed, physically healthy patients; however, these results

51

could also indicate that the CCL-D does not effectively measure negative thinking in
patients who are post-myocardial infarction.
4. Comparison of the strengths and weaknesses of the measures
The three instruments reviewed in this paper each have strengths and
weaknesses (see Table 4.3). All three measures have evidence for internal consistency
reliability and four types of construct validity: factorial, convergent, divergent, and
concurrent validity. With regard to internal consistency, all three measures demonstrated
strong Cronbach’s alphas (greater than 0.90) among various populations, providing good
evidence of internal consistency reliability. The strong Cronbach’s alphas could reflect
possible redundancy, but it is also possible that these Cronbach’s alphas could be due
to strong internal consistency rather than redundancy, as reflected in the item-total
correlations reported by some authors.23,24
With regard to factorial validity, a component of construct validity, each
instrument displayed a different number of dimensions of negative thinking. The CCI
contained four dimensions: the classic cognitive triad of negative thoughts of the self,
world, future, plus an additional dimension—negative thoughts of withdrawal from
others. The ATQ also displayed four dimensions; however, these dimensions reflected
only two components of the cognitive triad: negative views of the self and future. The
CCL as a whole showed evidence of two dimensions: negative thinking of depression
and anxiety. The CCL-D subscale was not subjected to its own factor analysis, so it is
not known how many dimensions of depressive negative thinking it contains.
The CCI, ATQ and CCL-D all have evidence supporting convergent validity with
measures of depressive symptoms. The instruments also have strong support for
concurrent validity as evidenced by the ability to discriminate between patients with and
without depression; however, the instruments have varying levels of support for
divergent validity. The CCI exhibited divergent validity with a measure of IQ, but the
authors did not test its divergent validity with anxiety. The ATQ has conflicting evidence
regarding its divergent validity with anxiety; therefore, it is not clear whether the ATQ can
distinguish negative thoughts of depression from those of anxiety. In contrast, Beck e
al.23 specifically designed the CCL to discriminate between negative thoughts found in
depression and anxiety. Since then, researchers have demonstrated strong evidence of
divergent validity of the CCL-D with anxiety among clinical and non-clinical populations.
The length of the CCI (45 items) and the ATQ (30 items) make them less
practical for use in research and particularly in clinical settings. In addition, researchers
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have not described whether the 11 positive buffer items on the CCI are necessary. In
contrast, the CCL-D is brief (14 items), making it easier to administer in a clinic setting or
research trial.
Researchers have yet to provide strong support for the reliability and validity of
these three measures among populations with a chronic physical condition, such as in
patients with HF. The reliability and validity of the CCI has not been tested in patients
with chronic physical conditions. The ATQ has been shown to have good internal
consistency reliability among Chinese patients with a chronic physical condition, but its
construct validity has not been tested among patients with a chronic physical condition.
The reliability and validity of the CCL-D have been tested among patients who are
physically ill; however, results from two studies have demonstrated that depressed
patients who are physically ill have significantly lower mean scores on the CCL-D when
compared to depressed psychiatric patients.25, 26 These results may indicate that
depressed patients with a physical illness have lower levels of negative thinking. On the
other hand, these results could raise concerns regarding the ability of the CCL-D to
effectively measure negative thinking in patients with a chronic physical condition such
as HF.
The CCI and CCL-D were developed with a psychiatric population, while the ATQ
was developed with undergraduate students. Heart failure is a chronic physical
condition that increases in prevalence with age and is the most common reason for
hospitalization in elderly adults.27, 28 It is possible that the ATQ’s items, generated by
college students, may not capture negative thinking found in older patients with a chronic
physical condition. For example, patients with HF have described negative thoughts
such as, “I’m a burden to my family,” “I have nothing to offer anymore,” and “Useless, I’m
just no good.”13 These thoughts may not be reflected by questionnaires that were
developed in physically healthy populations; however, all three instruments have been
tested in a variety of populations, including patients with mental illness. Therefore, it may
only be necessary to collect more psychometric data to support the reliability and validity
of these instruments among patients who have chronic HF.
5. Recommendations for the measurement of negative thinking in heart failure
In summary, the CCI, ATQ, and CCL-D have good evidence of reliability and
validity among clinical and non-clinical populations. The CCI has the greatest potential
for measuring negative thinking in patients with HF. This instrument has the advantages
of being developed with a clinical psychiatric population and captures a wide range of
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negative thinking content: negative thoughts about the self, world, future, and withdrawal
from others. In contrast, the ATQ was developed with undergraduate students, and
factor analysis has revealed that it only measures two components of Beck’s cognitive
triad. Although the psychometric properties of the CCI have not been tested among
patients with chronic physical illness, the CCI is preferred over the CCL-D because
results from several studies raise questions regarding the construct validity of the CCL-D
for measuring negative thinking in patients with a chronic physical condition.
Although the CCI demonstrated the best potential for measuring negative
thinking in patients with HF, the CCI in its current form is too long to be clinically useful.
Future research is needed to develop a shortened version of the CCI for use in clinical
research and practice. It is suggested that researchers use a combination of strategies
to determine which items to retain, including: exploratory factor analysis, corrected itemtotal correlations, Cronbach’s alpha if the item were deleted, and examination of means
and standard deviations of items to examine variability or lack thereof.
Following the development of a shortened version of the CCI, studies are needed
to: 1) provide evidence for internal consistency reliability of the CCI as a measure of
negative thinking in patients with HF, 2) examine the dimensionality of the CCI via
confirmatory factor analysis to determine if the four original dimensions are retained in a
sample of patients with HF who have depressive symptoms, 3) provide evidence for
convergent validity with depressive symptoms and divergent validity with anxiety among
patients with HF, and 4) determine whether the CCI is sensitive to changes in negative
thinking in patients with HF as a result of intervention.
6. Conclusion
Negative thinking is a modifiable target for the treatment of depressive symptoms
in patients with HF. In order to determine the effectiveness of interventions designed to
reduce negative thinking in patients with HF, researchers need a reliable and valid
instrument to measure negative thinking. The CCI has excellent potential for measuring
negative thinking in patients with HF. However, research is needed to shorten the CCI
and examine its psychometric properties of the CCI among patients with HF before it can
be recommended for routine use to measure negative thinking in this population.
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Table 4.1: Description of three instruments of negative thinking
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Instrument
(Year)
Crandell
Cognitions
Inventory1
(1986)

No. Items

Response Options

Scoring and Range

Sample Item

Normative Values*

34 negative
items; 11
positive
buffer
items

Indicate the
frequency of each
thought on a scale
from 1 (almost never)
to 5 (almost always)

I’ve made
such a mess
of my life.

Crandell and Chambless1
• Depressed psychiatric
patients: 116 ± 20.1
• Non-depressed psychiatric
patients: 74.2 ± 21.4
• Normal controls: 44.6 ± 8.3

Automatic
Thoughts
Questionnaire17
(1980)

30 negative Over the past week,
items
rate the frequency of
each thought on a
scale from 1 (not at
all) to 5 (all the time)

Total scores are
scored by summing
the item responses
to the 34 negative
items (11 buffer
items are not
scored)
Range = 34 - 170
Total scores are
calculated by
summing the 30 item
responses
Range = 30-150

It’s just not
worth it.

Cognition
ChecklistDepression23
(1987)

14 items

Total scores are
calculated by
summing the 14
responses
Range = 14-70

I don’t
deserve to be
loved.

Hollon and Kendall17
• Depressed college students:
79.6 ± 22.3
• Non-depressed college
students: 48.6 ± 10.9
Dozois et al.29
• Elderly: 41.6 ± 13.7
• Women: 53.5 ± 18.6
• Men: 48.4 ± 16
Harrell and Ryon20
• Depressed psychiatric
outpatients: 88.9 ± 21.2
• Non-depressed psychiatric
outpatients: 42.4 ± 10
• Non-depressed medical
outpatients: 38.4 ± 8.2
Beck et al.23
• Depressed psychiatric
outpatients: 54.8 ± 9
• Anxious psychiatric
outpatients: 45 ± 7.7

Frequency of each
thought on a scale
from 1 (“never”) to 5
(“always”)Indicate
how often each

Table 4.1 (Continued)
Instrument
(Year)

No. Items

Response Options
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thought occurs on a
5-point scale ranging
from 0 (never) to 4
(always) during
specific situations
(being with a friend
or attending a social
occasion) or
regardless of the
situation. No specific
time frame is given
for the situation
recall.
*Normative values are given as mean ± standard deviation

Scoring and Range

Sample Item

Normative Values*
Martens et al.26
• Depressed psychiatric
outpatients: 34.9 ± 11.9
• Depressed post-MI patients:
28 ± 9.6
• Non-depressed post-MI
patients: 17.8 ± 8.5
Clark et al.25
• Depressed hospitalized
medical patients: 12.2 ± 9.1
• Non-depressed hospitalized
medical patients: 5.1 ± 7.2
• Healthy controls: 4.5 ± 6.2

Table 4.2 (Continued)
4.2: Psychometric properties of three measures of negative thinking
First Author
(date)

Purpose

Design

Sample

Reliability

Crandell Cognitions Index (CCI)
Cross-sectional
N = 212
Cronbach’s
Psychiatric
alpha =
depressed group,
0.95
psychiatric nondepressed group,
normal control
group
Females 16%

To develop a
measure of
depressive selfstatements

Crandell1
(1980)

To test the
validity of the
CCI among
women

Cross-sectional

N = 65 Outpatients
with agoraphobia
with panic disorder
Female 82%

Not
reported

Peden7
(2000)

To test the
effectiveness of
a cognitive
behavioral
group
intervention on
depressive
symptoms
To determine
predictors of
depressive
symptoms in

Experimental,
repeatedmeasures

N = 92
College women

Cronbach’s
alpha =
0.95-0.97

Cross-sectional

N = 205
Low-income single
mothers

Cronbach’s
alpha =
0.97
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Crandell1
(1980)

Peden4
(2004)

Evidence of
Validity

Concurrent validity,
convergent and
divergent validity,
and factor validity
were supported

Convergent validity
was supported: CCI
was strongly
correlated with the
BDI
Not reported

Convergent validity:
CCI strongly
correlated with the
BDI, CES-D,

Comments

The authors did
not describe
support for
content validity;
however, items
were developed
based on Beck’s
Cognitive Model
of Depression
This study was
reported in the
same journal
article as above
The intervention
group
experienced a
significant
decrease in CCI
scores at one
month and six
months
Divergent
validity was not
evaluated in this
study.

Table 4.2 (Continued)
First Author
(date)

Purpose

Design

Sample

Reliability

low-income
single mothers
Peden30
(2005)
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17

To test a
cognitive
behavioral
group
intervention on
depressive
symptoms

Hollon
(1980)

To develop an
instrument that
measures
automatic
thoughts of
depression

Dobson31
(1983)

To test the
psychometric
properties of

Experimental,
repeated
measures

N = 136
Low income, single
mothers

Cronbach’s
alpha =
0.94-0.97

Automatic Thoughts Questionnaire (ATQ)
Cross-sectional
N = 348
Split half
College students
coefficient =
Female 42%
0.97;
coefficient
alpha =
0.96;
item-total
correlations
ranged from
0.47 to
0.78
Cross-sectional
N = 456
Cronbach’s
College students
alpha =
Female 49%
0.96

Evidence of
Validity
Everyday Stressors
Index, and
Rosenberg SelfEsteem Scale
Not reported

Comments

The authors
found a
decrease in
negative thinking
in the
intervention
group at one
month and six
months

Convergent validity
was supported but
divergent validity
(with anxiety) was
not supported.
Factor validity was
supported.

There was a low
percentage of
students with
depressive
symptoms
(7.5%);
depression was
not diagnosed
with a diagnostic
interview

Convergent validity
was supported: the
ATQ was strongly

The ATQ had
stronger support
for construct

Table 4.2 (Continued)
First Author
(date)

Purpose

Design

Sample

three cognitive
assessment
scales
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Harrell20
(1983)

To test the
psychometric
properties of
the ATQ in a
clinical sample

Cross-sectional

Lamberton22
(2008)

To determine
whether anxiety
and depression
can be
differentiated
by thought
content

Cross-sectional

N = 61
Adult outpatients
divided into three
groups:
depressed, nondepressed
psychiatric, and
non-depressed
patients who were
seeking medical
care
Female 56%
N = 135
Outpatients with
depressive
disorder, anxiety
disorder, or both
Female 55%

Reliability

Evidence of
Validity

(males) and
0.95
(females)

correlated with the
BDI (r = 0.62, p <
.001)

Split-half
coefficient =
0.96
Cronbach’s
alpha =
0.98
Item-total
correlations
ranged from
0.56 to 0.91
(p = .001)

Convergent validity
was supported:
depressed patients
had higher ATQ
scores than nondepressed patients.
Concurrent validity
was supported: ATQ
correctly classified
93.1% of patients.

Not
reported

Convergent and
divergent validity
were supported:
ATQ was strongly
correlated with BDI
(r = 0.63, p < .05)
and weakly

Comments

validity and
reliability than
two other
cognitive
measures: the
Dysfunctional
Attitude Scale
and the
Interpretation
Inventory
Patients were
separated into
groups based on
BDI scores and
a clinical
depression
rating given by a
therapist

Table 4.2 (Continued)
First Author
(date)

Purpose
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Wong21(2007) To test the
efficacy of
cognitive
behavioral
group therapy
on depressive
symptoms in
patients with
chronic
physical illness
23

Beck (1987)

To develop and
test the
psychometric
properties of
the CCL

Design

Randomized,
controlled trial

Sample

N = 73
Chinese patients
with chronic
physical illness
Female 75%

Reliability

Cronbach’s
alpha =
0.96

Evidence of
Validity
correlated with the
Beck Anxiety
Inventory (r = 0.17,
p < .05)
Not reported

Comments

The authors
used a Chinese
version of the
ATQ but did not
specify how it
was translated
and validated

Cognition Checklist- Depression subscale (CCL-D)
Cross-sectional
N = 618
Cronbach’s Convergent and
The CCL also
Outpatient
alpha =
divergent validity
contains an
psychiatric patients 0.92;
were supported: the anxiety subscale
Female 55%
CCL-D was strongly
Average
correlated with the
corrected
HAM-D (r = 0.62, p
item-total
< .001) and weakly
correlation
correlated with the
= 0.65;
HAM-A (r = 0.37, p <
Test.001).
reliability
was tested
Concurrent validity
by
was supported: the
administerin CCL-D correctly

Table 4.2 (Continued)
First Author
(date)
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Steer24
(1994)

Purpose

Design

Sample

To test the
psychometric
properties of
the CCL in
psychiatric
outpatients and
university
students

Cross-sectional

N = 2,197
Psychiatric
outpatients (n =
1,907) and
university students
(n = 290)
Female 58%

Clark25 (1998) To compare
depressive and

Cross-sectional

N = 152
Depressed

Reliability

g the CCLD to 66
patients
after six
weeks: the
correlation
between the
two scores
was 0.76 (p
< .001)
Cronbach’s
alpha =
0.91-0.93;
Item-total
correlations
ranged from
0.56 to 0.85
in the
psychiatric
sample and
0.41 to 0.72
in the
student
sample

Not
reported

Evidence of
Validity

Comments

classified 83% of
depressed patients

Factor analysis
supported the
original two
dimensions (anxiety
and depression)
only in the outpatient
group.
Construct validity
was supported: the
CCL-D was strongly
correlated with the
BDI and HAM-D, but
only weakly
correlated with the
Beck Anxiety
Inventory and HAMA.
Among medical
patients, convergent

The results from
this study
provide
additional
support for the
strong
convergent and
divergent validity
of the CCL-D.

The CCL-D has
stronger support

Table 4.2 (Continued)
First Author
(date)

Purpose

Design

anxious
symptoms
among
physically ill
patients and
depressed
psychiatric
inpatients

Sample

Reliability

psychiatric
inpatients (n = 75),
hospitalized
medical patients
with chronic
physical illness (n
= 52), healthy
controls (n = 25)
Female 59%
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Martens26
(2006)

To describe
level of
negative
thinking in
patients who

Cross-sectional

N = 120
Non-depressed
post MI patients (n
= 40), depressed
post MI patients (n

Not
reported

Evidence of
Validity

Comments

validity was
supported but not
divergent validity;
the CCL-D was
strongly correlated
with the BDI and the
HADS-D (r = 0.77,
0.60, p < .001), but it
was strongly
correlated with
measures of anxiety
such as the HADS-A
(r = 0.69, p < .001).
In contrast, the CCLD showed good
evidence of
convergent and
divergent validity in
psychiatric
inpatients; the CCLD was weakly
correlated with
HADS-A (r = 0.29, p
< .05).
Not reported

for divergent
validity among
psychiatric
patients
compared to
medical patients.

The depressed
post-MI patients
had lower levels
of negative
thinking than

Table 4.2 (Continued)
First Author
(date)

Purpose

are post MI

Design

Sample

= 40), and
depressed
psychiatric
outpatients (n =
40)
Females = 38%

Reliability

Evidence of
Validity

Comments
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psychiatric
outpatients (28
vs. 34.9, p =
.013) after
controlling for
age, sex,
education, and
marital status
BDI = Beck Depression Inventory; CES-D = Center for Epidemiologic Studies Depression scale; HAM-A = Hamilton Rating Scale for
Anxiety; HAM-D = Hamilton Rating Scale for Depression; HADS-A = Hospital Anxiety and Depression Scale- Anxiety subscale;
HADS-D = Hospital Anxiety and Depression Scale- Depression subscale, MI = myocardial infarction

Table 4.3: Strengths and weaknesses of the three measures
Strengths
• Captures four dimensions of negative
thinking
• Evidence for internal consistency
• Evidence for convergent and
concurrent validity
• Developed with a clinical psychiatric
population

Weaknesses
• Psychometric properties have not been tested among
patients with chronic physical illness
• Divergent validity with anxiety has not been tested
• Possible redundancy
• Length (45 items)

Automatic
Thoughts
Questionnaire

• Evidence for internal consistency
• Evidence for convergent, divergent,

• Validity has not been tested in patients with chronic

Cognitive
ChecklistDepression

• Evidence for internal consistency
• Evidence for convergent, divergent,

Crandell
Cognitions
Inventory

and concurrent validity
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and concurrent validity
• Brevity (14 items)
• Developed with a clinical psychiatric

population

•
•
•
•

physical illness
Developed with healthy undergraduate students
Captures only two dimensions of the cognitive triad
Possible redundancy
Length (30 items)

• Possible redundancy
• Evidence for lack of divergent validity among patients with

chronic physical illness
• Depressed patients with a chronic physical illness have

lower scores on the CCL-D than depressed psychiatric
patients, raising questions regarding its validity among
patients with chronic physical conditions

CHAPTER FIVE:
Evaluating the Psychometric Properties of a Measure of Negative Thinking in
Patients with Heart Failure
1. Introduction
Heart failure (HF) is a chronic condition which is increasing in prevalence and
incidence worldwide.1 Depressive symptoms are common in patients with HF; up to 48%
of patients with HF experience symptoms of depression,2 while 20% have major
depressive disorder.3 Both depressive symptoms and depression have a profound effect
on morbidity, mortality, and health-related quality of life among patients with HF.2
Patients with HF who experience depressive symptoms have a two-fold increase in the
risk of death compared to patients who do not have depressive symptoms.3
Negative thinking is a type of cognition in which the individual experiences
automatic, repetitive thoughts regarding the self, world, future, and withdrawal from
others.4, 5 Negative thinking is a risk factor for depressive symptoms,6, 7 and the presence
of negative thinking in major depressive disorder lessens the response to treatment for
depression.8 In a qualitative study, we found that patients with HF who have depressive
symptoms described experiencing negative thinking, which worsened the depressed
mood. Examples of negative thoughts described by patients with HF who were
experiencing depressive symptoms include “I have nothing to offer anymore,” “I’m a
failure,” and “I can’t justify my existence.”9
Cognitive therapy, which focuses on the reduction of negative thinking, was
developed by Beck in 1967 and has been shown to be an effective treatment for
depression in the general population.4, 10 Cognitive therapy is based on Beck’s cognitive
model of psychopathology.11 The main tenet of the cognitive model is that each
psychological disorder has a distinct cognitive content. For example, negative thinking of
depression focuses on negative thoughts about the self, world and future, while negative
thinking of anxiety focuses on a theme of danger. Researchers have proposed that
cognitive therapy may be an effective treatment for depressive symptoms in patients
with HF.12 However, in order to test the effects of cognitive therapy on depressive
symptoms in patients with HF, researchers need a reliable and valid instrument for
measuring negative thinking in this population.
The Crandell Cognitions Inventory (CCI) has been used to measure negative
thinking in psychiatric outpatients, healthy adults,5 low income single mothers,6 and
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college women.13 There is no evidence for the reliability and validity of this instrument as
a measure of negative thinking in patients with chronic HF. Furthermore, researchers
have not tested the divergent validity of the CCI with anxiety. Therefore, the purpose of
this study was to evaluate psychometric properties of the Crandell Cognitions Inventory
among patients with HF. The specific aims of this study were to 1) determine the
reliability and internal consistency of the CCI, and 2) evaluate the construct validity of the
CCI by examining the dimensionality of the CCI and testing the following hypotheses in
patients with HF: (a) patients with depressive symptoms will have higher levels of
negative thinking than patients without depressive symptoms, (b) patients will
demonstrate a dose-response relationship between depressive symptoms and negative
thinking, and (c) the correlation between the CCI and depressive symptoms will be
stronger than the correlation between the CCI and anxiety symptoms.
2. Methods
2.1. Design
This study was nested in a clinical trial testing biofeedback and cognitive therapy
in patients with HF (Biobehavioral Intervention in Heart Failure, NIH, NINR R01
NR008567). Institutional Review Board approval was obtained both for the original study
and this data analysis. Only baseline data were used for data analysis.
2.2. Sample and setting
The sample consisted of 179 outpatients with a confirmed diagnosis of impaired
left ventricular systolic HF or preserved systolic function HF. Patients were recruited
from June 2004 to May 2009 from the cardiology clinic at an academic medical center as
well as a Veteran’s Administration cardiology clinic. Patients were eligible for enrollment
if they were on stable doses of HF medications for at least three months and were not
referred for cardiac transplantation. Patients were excluded for valvular or peripartum HF
etiology, myocardial infarction or stroke within the past three months, major stroke
sequelae, or coexisting terminal illness. Informed consent was obtained and patients
completed questionnaires at a General Clinical Research Center. Research associates
were present at all times to answer questions and confirm that no items were
inadvertently skipped.
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2.3. Measures
2.3.1. Negative thinking
Negative thinking was defined as cognitions about the self, world, future, and
withdrawal from others, and was measured using the Crandell Cognitions Inventory
(CCI).5 The CCI is a 45-item scale that contains of 34 negative items and 11 positive,
non-scored, “buffer” items. Patients are asked to endorse how frequently they
experience a thought on a scale from 1 (almost never) to 5 (almost always). Total scores
are calculated by summing the item responses to the 34 negative items. Higher scores
indicate a greater frequency of negative thinking.
The CCI was developed by Crandell and LaPointe in 1979 with a sample of
depressed psychiatric patients, non-depressed psychiatric patients, and normal
controls.5 Researchers have demonstrated strong evidence for the reliability of the CCI
among psychiatric patients, healthy adults, college women, and single mothers.5, 6, 13
Crandell and Chambless5 stated that the CCI displayed good internal consistency;
however, item-total correlations for the CCI have not been reported.
Researchers have examined the validity of the CCI using factor analysis,
criterion-related validity and construct validity.5 Crandell and Chambless theorized that
the CCI would have three dimensions with factor analysis: negative thoughts about the
self, world, and future. However, factor loadings revealed four dimensions: self-rated
inferiority, helplessness, hopelessness, and detachment from others. These results led
Crandell and Chambless to add negative thoughts about withdrawal from others to their
conceptual definition of negative thinking.5
Crandell and Chambless have found good evidence for criterion-related and
construct validity of the CCI.5 The CCI was able to correctly predict the classification
(depressed psychiatric patients, non-depressed psychiatric patients, and normal
controls) of 92.5% of the sample. Construct validity was tested with convergent and
divergent validity; researchers demonstrated that the CCI strongly correlates with
depressive symptoms as measured by the Beck Depression Inventory.5, 6 Crandell and
Chambless5 also found evidence that the CCI has divergent validity with measures of
IQ.5 However, researchers have not explored the divergent validity of the CCI with
regards to anxiety symptoms.
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2.3.2. Depressive symptoms
Depressive symptoms were defined as clinically significant symptoms of
depression that can exist with or without the presence of major depressive disorder.14
The Beck Depression Inventory version II (BDI)15 was used to measure depressive
symptoms. The BDI is a 21-item questionnaire that assesses the presence and severity
of depressive symptoms. Patients who score greater than 13 are considered to have
clinically significant depressive symptoms. BDI scores can also be used to categorize
people into 4 groups; those with no symptoms (0-13), mild (14-19), moderate (20-28),
and severe depressive symptoms (29-63). The original version of the BDI has been
shown to predict mortality and hospitalizations in patients with HF.16 The Cronbach’s
alpha for our sample was 0.88, providing evidence of adequate reliability.
2.3.3. Anxiety symptoms
Anxiety symptoms were defined as the negative emotional response to a
perceived threat.17 Anxiety symptoms were measured with the state anxiety subscale of
the Brief Symptom Inventory (BSI).18 The BSI anxiety subscale consists of six items.
Patients rate each symptom on a 5-point scale (0-4) of distress ranging from 'not at all' to
'extremely'. Item scores are summed and the mean obtained. The possible range of
mean scores for the subscale is 0 to 4, with higher scores indicative of higher levels of
anxiety. Researchers have demonstrated evidence for internal consistency, reliability,
factor validity, and construct validity of the BSI anxiety subscale among medically ill
patients.18, 19
2.4. Data analysis
Data analysis was conducted using SPSS version 16. The baseline
characteristics of the sample were described using percentages, means, and standard
deviations. The homogeneity or internal consistency of the CCI was assessed using
Cronbach’s alpha. Alpha coefficients greater than 0.70 were considered to indicate
adequate internal consistency, while coefficients greater than 0.90 were considered to
indicate item redundancy. Corrected item-total correlations were also used to determine
the internal consistency of the CCI. An acceptable coefficient for item-total correlations
was greater than 0.20.20
Dimensionality was assessed using principal components analysis with direct
oblimin rotation because correlations between factors were assumed. Factors would be
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retained for rotation if they had an eigenvalue of greater than one, and if the factors were
located above the elbow on the scree plot.
To further assess construct validity of the CCI, we tested three hypotheses. First,
independent t-test was used to determine whether patients with depressive symptoms
had higher levels of negative thinking than patients without depressive symptoms.
Second, one-way analysis of variance and post-hoc comparisons using the Tukey HSD
test were used to evaluate whether patients demonstrate a dose-response relationship
between depressive symptoms and negative thinking. Third, Pearson correlation
coefficients were used to test the relationships among CCI scores, depressive
symptoms, and anxiety symptoms.
3. Results
3.1. Sample characteristics
Sample characteristics are described in Table 5.1. The mean level of negative
thinking in our sample was 58.6 ± 24.7. The potential range for the CCI is 34 to 170; the
range for our sample was 34 to 158. Approximately 24% of the sample (n = 42)
experienced clinically significant depressive symptoms based on BDI scores.
3.2. Reliability
Cronbach’s alpha for the CCI was 0.96, indicating adequate internal consistency,
but possible redundancy of items. The corrected item-total correlations for each of the
items were all greater than 0.4, indicating that each of the items contributed to the scale
(Table 5.2).
3.3. Construct validity
3.3.1. Principal components analysis
The 34 items were subjected to principal components analysis. Based on the
scree plot, one primary component emerged that explained 46% of the variance (see
Figure 5.1). Three other components had eigenvalues greater than 1. These
components explained an additional 5%, 4%, and 3% of the variance. When the
component matrix was examined, all of the items loaded strongly on the first component.
A few items loaded on components two through four but these loadings were weaker
than the loadings for the first component. Additionally, only one factor was located above
the elbow on the scree plot. These results indicate that the CCI exhibited only one
component; therefore, direct oblimin rotation was not performed.
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3.3.2. Hypothesis testing
The level of negative thinking among patients with depressive symptoms was
higher than that of patients without depressive symptoms (86.7 ± 25 vs. 50 ± 26, p <
.001). There was a dose-response relationship between depressive symptoms and
negative thinking. Patients with mild moderate, and severe depressive symptoms had
progressively higher levels of negative thinking when compared to patients with no
depressive symptoms, providing evidence for convergent validity (F = 61.8, p < .001).
Post-hoc tests revealed significant differences in levels of negative thinking between
each of the groups (see Figure 5.2). The correlation between negative thinking and
depressive symptoms (r = .732, p = .01) was slightly higher than that of negative thinking
and anxiety symptoms (r = .595, p = .01), providing evidence for divergent validity.
4. Discussion
This was the first study to examine the psychometric properties of an instrument
that measures negative thinking in patients with HF. The results of our study
demonstrate that the CCI has adequate internal consistency and reliability in patients
with HF. However, the high Cronbach’s alpha suggests that there may be redundancy in
the items. The CCI contains 45 items and is longer than other measures of negative
thinking, such as the Cognitions Checklist- Depression scale (14 items).11 To improve
the clinical and research utility of the CCI, future researchers should develop and test
the reliability and validity of a shortened version. Researchers also should identify
whether the non-scored, positive buffer items are necessary.
Only one strong component emerged in our principal components analysis. Our
findings contrast with those of Crandell and Chambless,5 who found that the CCI
contained four components—negative thoughts about the self, world, future, and
withdrawal from others.5 It is possible that we were unable to adequately assess the
dimensionality of the CCI due to a relatively small number of patients in our study with
clinically significant depressive symptoms (n = 42). Additional factor analyses of the CCI
that include samples of patients with HF who have a high level of depressive symptoms
are needed.
We hypothesized that patients with depressive symptoms would have higher
levels of negative thinking compared to patients without depressive symptoms.
Furthermore, we hypothesized that patients with mild, moderate, and severe depressive
symptoms would have progressively higher levels of negative thinking compared to
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patients with no depressive symptoms. Our findings supported both hypotheses. Most
compelling was the dose-response relationship between negative thinking and
depressive symptoms. The observation that as levels of negative thinking increase
severity of depressive symptoms increased accordingly provides strong support for the
convergent validity of the CCI among patients with HF.
Finally, we provided evidence for divergent validity of the CCI with regards to
anxiety symptoms. Evidence of divergent validity with anxiety is important because in the
cognitive model, Beck proposes that depression and anxiety have separate, distinct
content.21 Thus a valid measure of depressive negative thinking in patients with HF
should be more strongly correlated with depressive symptoms than anxiety symptoms.
In our sample of patients with HF, the CCI was strongly correlated with both depressive
symptoms and anxiety symptoms. It is possible that the strong correlation between the
CCI and both measures reflects frequent comorbidities of depressive symptoms and
anxiety in patients with HF.22 However, the correlation between the CCI and depressive
symptoms was slightly stronger than that of the CCI and anxiety, providing some support
for divergent validity of the CCI with anxiety symptoms.
Finally, one limitation should be noted. We did not use a diagnostic interview to
categorize patients as depressed or non-depressed. Therefore, we could not evaluate
the concurrent validity of the CCI by testing its ability to distinguish levels of negative
thinking between depressed and non-depressed patients with HF. The inclusion of a
diagnostic interview for major depressive disorder would be beneficial in future
psychometric analyses of a shortened version of the CCI.
5. Conclusion
The findings from our study provide strong support for the reliability and validity
of the CCI as a measure of negative thinking in patients with HF. Depressive symptoms
remain a significant clinical problem in patients with HF, and negative thinking is a
potential target for the treatment of depressive symptoms in this population. We
recommend the CCI for use in research studies testing interventions that target the
reduction of negative thinking in patients with HF. Ongoing research in our group is
focused on determining whether CCI scores change over time as a result of
interventions that target negative thinking in both outpatients and inpatients with HF. We
also plan to develop and test a shortened version the CCI by eliminating redundant
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items. A shortened version will improve the CCI’s clinical practicality as a measure of
negative thinking among patients with acute and chronic HF.

Copyright © Rebecca L. Dekker 2010
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Table 5.1: Sample characteristics (N = 179)
Characteristic

Frequency (%) or
mean ± standard deviation
59 (33%)
60 ± 13
94 (52.5%)
35 (19.6%)

Female
Age
Married
Minority
Education level
Less than high school
34 (19%)
High school graduate
44 (24.6%)
Some college or greater
103 (56.4%)
Employment status
Employed
47 (26.3%)
Disability
36 (20.1%)
Retired
84 (47%)
Body Mass Index
32.5 ± 8.3
NYHA functional class
Class I
15 (8.4%)
Class II
75 (41.9%)
Class III
71 (39.7%)
Class IV
13 (7.3%)
Left ventricular ejection fraction
36.6 ± 14.8
Ischemic HF etiology
79 (44.1%)
Current smoker
31 (17.3%)
Months since diagnosed with HF
77 ± 84
Comorbidities
Prior myocardial infarction
88 (49.2%)
Atrial fibrillation
78 (43.6%)
Implanted cardiac defibrillator
63 (35.2%)
Stroke
38 (21.2%)
Chronic obstructive pulmonary
32 (17.9%)
disease
Diabetes
79 (44.1%)
Medications
ACE inhibitor
127 (70.9%)
Beta blocker
157 (87.7%)
Antidepressant
42 (23.5%)
Crandell Cognitions Inventory
58.6 ± 24.7
Beck Depression Inventory-II
9.9 ± 8.2
Brief Symptom Inventory- anxiety
0.61 ± 0.69
subscale
NYHA = New York Heart Association, HF = Heart failure, ACE = Angiotensin-converting
enzyme
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Table 5.2: Item-total correlations for the Crandell Cognitions Inventory (N = 152)
Item

1. I’m just a nobody
3. I’ll never feel good again
4. I sure have wasted the opportunities in my life
5. I don’t know what I should do
6. I’m always letting myself down
8. I’ve made such a mess of my life
10. Nothing ever works out for me anymore
11. Things really look hopeless
12. Why can’t I be happy?
13. It all seems so useless
15. I just don’t cut it
16. I sure am bored
17. My life is so confused, I’ll never straighten it out
18. I’m a burden to m family
20. I’ll never be happy with myself
22. There’s no way out of this mess
23. I don’t seem to have the energy to get through the
day
24. I really can’t do what’s expected of me
26. No one can know how alone I feel
27. I’ll never do as well as others
28. Everything I do is a failure
29. I don’t even feel like going out of the house
30. I’m a real disappointment to my family
32. I feel so detached; I just can’t communicate
33. I mess everything up
35. I know what I should do but I just can’t do it
36. Nothing’s ever going to work out for me
37. I feel trapped
38. Daytimes are bad but nighttimes are terrible
39. I just wish it would be all over
41. Nothing seems exciting anymore
43. I wish people would just leave me alone
44. Nobody cares about me
45. I feel so helpless
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Corrected
item-total
correlation
.555
.574
.722
.662
.772
.703
.700
.675
.778
.765
.739
.475
.786
.605
.702
.625

Cronbach’s
alpha if item
deleted
.963
.963
.962
.963
.962
.962
.962
.963
.962
.962
.962
.964
.962
.963
.962
.963

.639

.963

.680
.661
.624
.698
.533
.687
.658
.727
.554
.717
.739
.622
.600
.599
.540
.603
.654

.963
.963
.963
.963
.964
.963
.963
.963
.964
.962
.962
.963
.963
.963
.963
.963
.963

Figure 5.1: Scree plot of factors of the Crandell Cognitions Inventory in patients
with heart failure
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Figure 5.2: Dose-response relationship between depressive symptoms and
negative thinking in outpatients with heart failure*
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50

(A) No
depressive
symptoms
n = 137

(B) Mild (C )Moderate (D) Severe
depressive depressive depressive
symptoms symptoms symptoms
n = 20
n = 12
n = 10

*One-way analysis of variance, F = 61.8, p < .001
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A<B

p < .001

A<C

p < .001

A<D

p < .05

B<C

p < .001

B<D

p < .001

C=D

p = .003

Chapter Six:
A Brief Cognitive Therapy Intervention Improves Outcomes in Hospitalized
Patients with Heart Failure: A Randomized, Controlled Pilot Study
1. Introduction
Hospitalized patients with HF are at high risk for experiencing depression and
depressive symptoms. One-third of patients hospitalized with HF suffer from major
depressive disorder.1 The adverse effects of major depressive disorder and depressive
symptoms on mortality and morbidity in patients with HF have been well documented.2-6
In a meta-analysis, Rutledge et al. demonstrated that patients with HF and depressive
symptoms were twice as likely to die or experience a cardiac event when compared to
patients without depressive symptoms.3 Other researchers have found patients with HF
who report depressive symptoms during hospitalization are at higher risk for both shortterm and long-term mortality.2, 7 Depressive symptoms also have a negative impact on
health-related quality of life (HRQOL) among patients with HF.4 Interventions to treat
depressive symptoms in patients with HF are needed to improve survival and HRQOL.
Negative thinking, a modifiable risk factor for depressive symptoms, is a potential
target for intervention in patients with HF. Negative thinking, first described by Beck,8
can be defined as automatic and persistent negative cognitions about the self, world,
future, and interpersonal relationships.8, 9 In Beck’s cognitive model of depression, it is
postulated that negative thinking influences the emotional, behavioral, and somatic
symptoms of depression.10
Negative thinking has several adverse consequences in the general population.
First, negative thinking has been described as a risk factor for depressive symptoms.11, 12
Second, negative thinking exacerbates and maintains depressive symptoms, which
contributes to a downward spiral of worsening depressive symptoms that may end in
major depressive disorder.8, 13 Third, researchers have found that the presence of
negative thinking independently predicts a diminished response to treatment for
depression after controlling for history of depression and depressive symptoms at
baseline.14
Cognitive therapy (CT), the psychotherapeutic intervention based on the
cognitive model, alters depressive symptoms by redirecting negative thinking. CT has
been used successfully to treat depression in multiple populations.10, 15 Results from
previous studies indicate that brief CT interventions that use of thought-stopping and
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affirmations to decrease the level of negative thinking reduce depressive symptoms in
women at risk for depression.16, 17
The availability of a clinically feasible intervention that could be offered at the
bedside may increase clinicians’ ability to treat depressive symptoms in hospitalized
patients with HF. One potential, clinically feasible treatment of depressive symptoms in
this population is the use of a single, brief CT intervention focused on reducing negative
thinking using thought-stopping and affirmations. Therefore, the purpose of this study
was to test the short -term efficacy of a brief CT intervention aimed at decreasing
negative thinking for the treatment of depressive symptoms in hospitalized patients with
HF. We hypothesized that patients who received the brief CT intervention focused on
reducing negative thinking would report lower levels of depressive symptoms and
negative thinking, and better HRQOL and cardiac event-free survival at one week and
three months compared to a usual care group.
2. Methods
2.1 Design
A randomized, controlled, repeated measures design was used to determine the
short-term efficacy of a brief CT intervention. We followed the CONSORT (Consolidated
Standards of Reporting Trials) guidelines.18 The University of Kentucky Institutional
Review Board and the Institutional Review Boards at participating hospitals approved
the trial. All patients provided informed consent. Enrollment began February 2009 and
ended December 2009; follow-up was completed in March 2010.
A sample size of 21 patients per group was determined by an a priori power
analysis estimate for a two-group univariate repeated measures ANOVA algorithm with
Greenhouse-Geisser correction.19 A large effect size was chosen based on data from a
prior study in which a large group difference in the short-term effect of a similar brief
intervention was reported.20 With 21 subjects per group and an alpha level of .05, the
power of the ANOVA F tests would be at least 95% to detect a main effect for group, a
main effect for time, and the group by time interaction
2.2 Sample
Patients age 21 and older who were hospitalized with a primary or secondary
diagnosis of HF at Central Baptist Hospital or Saint Joseph Hospital in Lexington, KY,
were screened for study eligibility. Patients were candidates for inclusion if they had a
confirmed diagnosis of preserved or non-preserved systolic function HF. We excluded
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patients with co-existing terminal illness, end-stage HF (defined as mechanical pump
support, continuous at home inotropic infusions, referral for heart transplant, or hospice
care), cognitive impairment, and self-reported severe depression or suicidal ideation.
Eligible patients were approached by the principal investigator (PI) on the second
day of hospitalization or later. Recruitment was delayed if the patient was experiencing
hypotension (blood pressure <80 mm Hg), a pain level of ≥ 5 on the 0-10 pain scale, or
admission to an intensive care unit until medically stable. Patients who agreed to be in
the study and provided written consent were screened for depressive symptoms with the
Beck Depression Inventory version II (BDI). Those patients with mild to moderate
symptoms of depression (BDI score 10-28) were enrolled in the trial. Participation for
patients with no depressive symptoms or severe depressive symptoms ended after the
baseline assessment; patients with severe depressive symptoms were referred to the
attending physician for treatment. Two items on the BDI related to low energy and
fatigue were not included in the upper cut-off score because patients admitted to the
hospital with HF often report or experience HF-related fatigue.
2.3 Randomization
A random allocation sequence was compiled using a true random number
generator.21, 22 Group assignments were placed in sealed, numbered envelopes. The
investigators were blinded to the random allocation sequence. The PI enrolled the
patient, completed the baseline assessment, and calculated the baseline BDI score.
Immediately after completion of the baseline assessment, the PI opened the envelope to
determine group assignment. Patients and investigators were not blinded to group
assignment.
2.4 Procedure
Patients were approached by the PI, who introduced herself and explained the
purpose of the visit. After written informed consent was obtained, the baseline data
collection took place at the patient’s bedside. A chart review was conducted to obtain
clinical and sociodemographic variables. Privacy was maintained throughout data
collection by allowing patients to determine which family members or significant others
they would like to have in the hospital room during study procedures.
Both groups completed baseline questionnaires to measure depressive
symptoms, negative thinking, and HRQOL. The PI read the questionnaires out loud for
patients who needed assistance due to vision impairment, fatigue, or difficulty reading.
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The PI calculated the BDI score and patients with mild to moderate depressive
symptoms were randomized. Patients with severe depressive symptoms were
encouraged to talk to their healthcare provider about their depressive symptoms, and the
staff nurse, charge nurse, attending physician, and primary care physician were
informed of the patient’s high level of depressive symptoms. Patients in the intervention
group received the individual intervention prior to discharge, at a time convenient to the
patient. Patients in the control group received usual care.
One week after discharge, patients received a phone call reminder to complete
and mail the one-week questionnaires. Patients who needed assistance were given the
option of having the questionnaires read out loud over the phone. At three months,
patients completed the questionnaires again by phone or mail, and patients were asked
about current antidepressant medication use, hospitalizations, and emergency
department visits that occurred since the baseline assessment. Patients were
reimbursed $20 for the baseline assessment and $10 for each follow-up assessment.
2.5 Intervention
The intervention consisted of a single, brief, one-on-one CT session that took
place in the hospital and a short telephone booster that took place one week post
discharge. The brief CT session and booster were delivered by the PI, a Master’sprepared cardiovascular nurse, in collaboration with a PhD-prepared psychiatric clinical
nurse specialist, who had tested a similar intervention with women at risk for depression
in several randomized, controlled trials.16, 17 Previous qualitative work guided the design
of the intervention.23 A colorful, 13 page flip chart with photos was used to guide the
written script of the intervention. Patients also received a color booklet to take home.
The script of the intervention followed six simple steps focused on reducing
negative thinking using thought-stopping and affirmations (see Table 1). Patients were
allowed to choose whether or not they would like a family member or significant other to
be present during the intervention, which lasted approximately 30 minutes.
The booster CT session took place during the one week post discharge phone
call (after the one week questionnaires were filled out) and lasted 5-10 minutes. During
the booster, the PI talked with patients about negative thoughts they have been
experiencing and asked about their experiences with the technique of thought-stopping
followed by affirmation. The PI reinforced the technique and reminded patients of the
importance of using thought-stopping and affirmations.
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2.6 Usual care
Patients in the control group received usual care, which consisted of standard
evidence-based care for HF according to the American Heart Association/American
College of Cardiology 2005 guidelines24 and the Joint Commission of Healthcare
Organizations.25 All patients with HF received individual discharge teaching on HF care,
which included brief written instructions on the emotional consequences of living with
HF. All patients were also offered the assistance of a chaplain if desired. In addition,
patients in the control group received approximately 40-60 minutes of attention from the
PI during recruitment, enrollment, and the baseline assessment.
2.7 Outcome measures
2.7.1 Depressive symptoms
The primary outcome was depressive symptoms, which was defined as selfreported symptoms that may exist with or without the presence of major depression.26
The Beck Depression Inventory version II (BDI was used to measure depressive
symptoms at baseline, one week post-discharge, and three months. The BDI contains
21 items. Scores range from 0-63, with a score of 0-13 indicating none to minimal
depressive symptoms, 14 to 28 indicating mild to moderate symptoms, and 29-63
indicating severe symptoms.27 The BDI has well-established validity, reliability, and
internal consistency for measurement of depressive symptoms in medical and nonmedical populations.28, 29
2.7.2 Health-related quality of life
Health-related quality of life (HRQOL) was defined as a patient’s perception of
how HF has impacted the following domains of daily life: physical functioning, emotional
status, health perception, and symptom burden. The Minnesota Living with HF
Questionnaire (MLHFQ) was used to measure HRQOL. This instrument has been
demonstrated to be reliable and valid in patients with HF.30 Patients respond to 21-items
with the stem question: “Did your HF prevent you from living as you wanted during the
past month by.” The statements are rated from 0 (no impact) to 5 (most negative
impact). Total scores range from 0 to 105. Higher scores indicate worse HRQOL.
2.7.3. Negative thinking
Negative thinking was defined as negative cognitions about the self, world,
future, and withdrawal from others, and was measured using the Crandell Cognitions
Inventory (CCI).9 The CCI is a 45-item scale that consists of 34 negative items and 11
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positive, non-scored, buffer items. Patients are asked to endorse how frequently they
experience a thought. Total scores are calculated by summing the item responses to the
34 negative items; scores range from 34 to 170. Higher scores indicate a greater
frequency of negative thinking. Researchers have demonstrated evidence for the
reliability and validity of the CCI in psychiatric patients and healthy controls.9
2.7.4. Event-free survival
A secondary endpoint was three-month cardiac event-free survival, defined as
time to a combined end point of cardiovascular mortality, cardiovascular hospitalization,
or cardiovascular emergency department (ED) visit. Dates and reasons for death,
cardiovascular hospitalizations and ED visits were determined by medical record review
and patient interview. A cardiovascular rehospitalization or ED visit was defined as an
unanticipated admission for the following reasons: HF exacerbation, shortness of breath,
cardiovascular-related chest pain, myocardial infarction, syncope, dysrhythmias
(including internal cardiac defibrillator [ICD] firing), ICD or biventricular pacemaker
placement due to worsening HF, coronary artery disease, hypertension, and palpitations.
2.7.5. Additional variables of interest
To completely describe the sample and obtain data on potential confounding
variables, the following demographic information was collected at baseline: age, sex,
race/ethnicity, marital status, education level, and months since diagnosis. The following
clinical characteristics were determined by chart review: height, weight, smoking status,
most recent left ventricular ejection fraction, comorbidities, and medications on
discharge (i.e. drugs, doses, frequencies)..
New York Heart Association (NYHA) functional class and comorbidities were also
collected to further characterize the sample. NYHA functional class is a subjective
indicator of functional status and was determined by patient interview at baseline and
three months. Patients were assigned a classification of I (ordinary physical activity
causes no symptoms of fatigue, dyspnea, angina or palpitations), II (symptoms with
ordinary physical activity), III (symptoms occur with less than ordinary physical activity)
or IV (symptoms occur even at rest).31
2.8 Data analysis
Demographic and clinical differences between the groups were assessed using ttests or chi-square tests of association. Data analysis for each of the specific aims was
conducted using intent-to-treat. To determine the effects of the intervention, repeated
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measures ANOVA was used to compare levels of depressive symptoms, HRQOL, and
negative thinking at baseline, one week post-discharge and three months between the
two groups. The main effects for group, time, and group by time interaction were tested.
Cardiac event-free survival was calculated using Kaplan-Meier survival curves with the
log-rank test. Differences in the mean number of cardiac events between groups were
determined with an independent t-test. An alpha of .05 was considered statistically
significant for all analyses.
3. Results
3.1 Sample characteristics
A participant flow diagram is provided in Figure 6.1. Of the 407 patients who
were screened for eligibility, 327 were excluded. The most common reasons for
exclusion were cognitive impairment (n = 95), co-existing terminal illness (n = 34), and
end-stage heart failure (n = 17).
Eighty patients provided informed consent and were screened for depressive
symptoms. Of these 80 patients, 42 (53%) had mild-moderate depressive symptoms and
were retained in the study, while 33 patients (41%) with no depressive symptoms and 5
patients (6%) with severe depressive symptoms were excluded. The characteristics of
the final sample are provided in Table 6.2. The sample consisted of 42 patients with HF
(45% female, 66 ± 11 years, 75% NYHA Class III). The mean depressive symptom
score was 16.7 ± 6.7, which indicates mild depressive symptoms. One-third of the
patients had a history of depression noted in the chart, and 41% were taking
antidepressants at discharge.
There were no differences between intervention and control groups with regard
to sex, age, NYHA Class, ejection fraction, marital status, ejection fraction, medications,
and baseline depressive symptoms, negative thinking, or HRQOL. Patients in the control
group had a higher mean body mass index, and patients in the intervention group were
more likely to have prior coronary bypass graft surgery and co morbid chronic pulmonary
obstructive disease. There were no baseline differences between groups with regard to
depressive symptoms, HRQOL, and negative thinking.
Of the 41 patients for whom cardiac event-free survival data were collected, 19
patients (54%) experienced a cardiovascular event during the three month follow-up
period. Two patients died from worsening HF, 13 patients had at least one
cardiovascular hospitalization, and 4 patients visited the ED for cardiovascular reasons.
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3.2 Primary outcome
As shown in Table 6.3, BDI scores improved over time in both groups (p < .001);
however, there were no significant difference between groups. Figure 6.2 suggests a
trend for patients in the intervention group to have a faster improvement in depressive
symptoms compared to patients in the control group, but this trend was not significant.
3.3 Secondary outcomes
Table 6.3 also presents the data on HRQOL and negative thinking. Both groups
experienced significant improvements in HRQOL and negative thinking over time. There
were no significant group by time interactions for HRQOL or negative thinking. Although
Figure 6.3 and 6.4 appear to show trends toward faster improvement in HRQOL and
negative thinking in the intervention group compared to the control group, these trends
were not significant.
Patients in the intervention group had longer cardiac event-free survival
compared to the control group (Figure 6.5). At three months, 80% of patients in the
intervention group were alive without a cardiac event, compared to 40% of patients in
the control group (p = .048). Furthermore, the mean number of cardiovascular events
over the three month time period was higher in the control group compared to the
intervention group (0.8 vs 0.2, p < .008).
4. Discussion
Researchers have established that depressive symptoms contribute to poor
health outcomes in patients with HF.3 In this study, I tested the effects of a brief, clinically
feasible CT intervention that can be administered by nurses for the treatment of
depressive symptoms in hospitalized patients with HF. Patients in both groups
experienced a significant improvement in depressive symptoms after discharge, but
there were no differences between groups over time. It is likely that this was due to the
large natural improvement that occurs with depressive symptoms after hospitalization for
HF and attrition. Although the study was powered to detect differences in depressive
symptoms between groups, I did not expect patients in both groups to experience such a
large reduction in depressive symptoms during the follow-up period. In addition, data on
depressive symptoms were missing from five patients in the control group (2 patients
died, 2 patients declined further participation, and 1 was lost to follow-up) and 2 patients
in the intervention group (1 was lost to follow-up, 1 was too busy to complete the 3
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month questionnaires). Overall, the promising results of this pilot study support
replicating the study with a larger sample size.
We found that, in general, depressive symptoms improve soon after discharge in
patients who are hospitalized with HF. Few researchers have described the trajectory of
depressive symptoms in patients with HF. Koenig et al.32 found that although many
patients with HF and depression experience spontaneous remission within several
months after hospital discharge, 36% and 52% of patients continue to have symptoms of
mild and major depression, respectively. The main predictor of shorter time to remission
was lower levels of depressive symptoms. In our study, we enrolled patients with mild to
moderate symptoms and excluded those with high levels of depressive symptoms. The
mean level of depressive symptoms in our study was 16.. This relatively low level of
depressive symptoms could explain why both groups improved rapidly after discharge.
Future research is needed to determine whether brief CT interventions are beneficial in
patients with higher levels depressive symptoms who are less likely to improve on their
own.
Our finding that patients experience improvement in HRQOL after discharge is
consistent with findings from Riegel et al.,33 who combined data sets from nine
experimental and quasi-experimental trials to determine the trajectory of HRQOL after
hospitalization in patients who receive usual care. The investigators found that HRQOL,
as measured by the Minnesota Living with Heart Failure Questionnaire, naturally
improves by a mean of 13 points in the three months after hospital discharge. ,
We also found that the intervention group had the same improvement in HRQOL
as the usual care group. This result may be explained by findings from Riegel et al.,33
who found that only high-intensity interventions had an effect on HRQOL after
hospitalization. Similarly, a more intense dose of the CT intervention offered in this study
may be needed to improve HRQOL after discharge.
This is the first study to examine changes in negative thinking as a result of a CT
intervention in patients with HF. Although there was a trend toward faster improvement
in the intervention group and an increase in negative thinking in the control group after
discharge, there were no significant differences between groups. Previous researchers
have found that in women, negative thinking can be modified as a result of a similar CT
intervention that uses thought-stopping and affirmations.16, 17 It is probable that we were
unable to detect a difference between groups because of a small sample size and
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missing data on the CCI. During the follow-up time points, several patients were too ill to
complete all of the instruments, and in those cases the CCI was dropped from the
questionnaire administration because of its length. A reliable and valid shortened version
of the CCI would make it more practical for use in patients with an acute or chronic
physical health condition.
This study is the first to demonstrate that a brief, nurse-delivered CT intervention
has a measurable impact on cardiac event-free survival in patients with HF. It is not clear
why the intervention group experienced longer cardiac event-free survival when there
were no differences between groups on depressive symptoms, negative thinking, or
health-related quality of life. It is possible that patients in the intervention group
experienced improvements in an unmeasured construct such as positive thinking or
sympathetic nervous system activation.
Furthermore, we do not know why a survival benefit was demonstrated in our
small study when other investigators did not find a survival difference when testing CT in
a much larger sample. The ENRICHD35 investigators tested the effects of CT on survival
in 2,481 patients with cardiovascular disease who had recently experienced a
myocardial infarction and were diagnosed with clinical depression or self-reported poor
social support. Although patients in the intervention group experienced a significant
reduction in depressive symptoms as compared to the control group, there were no
differences in cardiac event-free survival between groups. Our study differs from the
ENRICHD study with regard to both patient population and timing of the cardiac
outcome. Whereas the ENRICHD investigators recruited patients who had recently
experienced a myocardial infarction, we enrolled patients who were experiencing an
acute exacerbation of HF and were highly vulnerable to cardiac events during the three
months post-hospitalization. In our study, we had an overall cardiac event rate of 54%,
which may have contributed to our ability to detect a difference in outcomes.
Furthermore, the ENRICHD investigators followed patients for an average of 29 months,
while we measured cardiac event-free survival for three months. Future research is
needed to test the effects of the brief CT intervention on long-term cardiac event-free
survival in patients with HF.
4.1 Limitations
Several limitations should be noted. First, this study needs to be replicated using
a larger sample before definitive conclusions can be drawn. Second, due to resource
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limitations, the follow-up questionnaires were administered by the same researcher (PI)
who also administered the intervention. However, several steps were taken to reduce
the potential for social desirability or researcher bias. The baseline assessment was
completed prior to randomization so that the PI was blinded to group assignment during
the first assessment. In addition, follow-up questionnaires were administered by mail
whenever possible, and the PI did not discuss the intervention with the patient during the
one-week and three-month assessment.
5. Conclusions
Our findings indicate that although depressive symptoms improve rapidly after
discharge, patients would benefit from a nurse-administered, brief CT intervention while
hospitalized for HF. This intervention is replicable, practical for the acute care setting,
and may improve short-term cardiac event-free survival in patients with HF. Future
research is needed to replicate this study using a randomized controlled trial that is
powered to detect differences in primary and secondary outcomes, includes patients
with higher levels of depressive symptoms, and incorporates a longer follow-up period.
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Table 6.1 Summary of the six steps of the brief cognitive therapy intervention
Step 1: Depression and heart failure
Description of symptoms of depression
Depression is common in people with heart failure
Bad news: Depression is bad for the heart
Good news: There are treatments for depression
Discussion question: “Do any of these symptoms of depression sound familiar to
you?”
Step 2: Thoughts, feelings, and behaviors
The connection between thoughts, feelings and behaviors
Thoughts can be false and negative, and these thoughts contribute to painful
feelings and negative behaviors of depression
Two real-life patient stories are told that demonstrate the link between a stressful
situation and negative thinking, feelings, and behaviors
Discussion question: “Do these stories sound familiar to you? Do you see how the
person’s negative thinking led to painful feelings and negative behaviors?”
Step 3: Your story
Interactive component: Patient is asked to describe a recent stressful situation
Discussion questions: “What kind of thoughts were going through your head? How
did these thoughts make you feel? Did you notice any behaviors?”
Step 4: Thought-stopping
Notice you have a negative thought
Snap your fingers or clap your hands and say, “Stop!”
By stopping the negative thought you help take away the painful feelings that go
with the thought
Interactive component: Patient practices the stop technique with the interventionist
Step 5: Affirmations
An affirmation is a short, simple phrase that states how life is at its very best
Use first person, present tense, and positive words; if you have a religious faith you
may use it in your affirmation
Interactive component: The patient comes up with 3-4 affirmations with the help of
the interventionist
The interventionist writes the affirmations on 2 brightly colored sticky notes: one for
the hospital room and one for the patient to take home
Step 6: Homework
Practice the stop technique every time you hear a negative thought
Hang the list of affirmations somewhere you will see it every day
For every negative thought, think at least 2 positive thoughts
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Table 6.2: Baseline characteristics of entire sample and patients randomly
assigned to the brief cognitive therapy intervention versus usual care*
Characteristic

Female
Age
Married
Minority
Education level
Less than high school
High school graduate
Some college or
greater
Employment status
Employed
Sick leave or disability
Retired
Body Mass Index
NYHA functional class
Class II
Class III
Class IV
Left ventricular ejection
fraction
Etiology of HF
Ischemic
Hypertensive
Idiopathic
Other
Smoking status
Never smoked
Former smoker
Current smoker
Second hand smoke
exposure
Months since diagnosed
with HF
Newly diagnosed with HF
in the past month
History of depression
History of anxiety
Comorbidities
Prior myocardial
infarction
Atrial fibrillation
CABG surgery
Biventricular

Overall
sample
(n = 42)
19 (45%)
66 ± 11
24 (57%)
4 (10%)

Intervention
group
(n = 21)
10 (48%)
68 ± 10
14 (67%)
2 (10%)

Usual care
group
(n = 21)
9 (43%)
64 ± 12
10 (48%)
2 (10%)

p
value

15 (36%)
12 (29%)
14 (33%)

10 (48%)
6 (30%)
5 (24%)

5 (25%)
6 (30%
9 (45%)

0.3

3 (7%)
15 (36%)
21 (50%)
31± 8.6

2 (10%)
9 (43%)
10 (48%)
28.2 ± 6.4

1 (5%)
6 (30%)
13 (65%)
33.8 ± 9.7

0.5

8 (19%)
31 (74%)
3 (7%)
39.5± 16.4

6 (29%)
15 (71%)
0 (0%)
40.8 ± 17

2 (10%)
16 (76%)
3 (14%)
38.1 ± 16.1

0.08

26 (62%)
8 (19%)
6 (14%)
2 (10%)

13 (62%)
4 (19%)
2 (10%)
2 (10%)

13 (62%)
4 (19%)
4 (19%)
0 (0%)

0.5

17 (41%)
14 (33%)
7 (17%)
12 (29%)

7 (33%)
9 (43%)
5 (24%)
6 (29%)

10 (50%)
8 (40%)
2 (10%)
6 (29%)

0.4

39 ± 56

45 ± 68

32 ± 37

13 (31%)

8 (38%)

5 (24%)

0.3

14 (33%)
13 (31%)

9 (43%)
8 (38%)

5 (24%)
5 (24%)

0.2
0.3

17 (41%)

8 (38%)

9 (43%)

0.8

19 (45%)
12 (29%)
17 (41%)

8 (38%)
10 (48%)
8 (38%)

11 (52%)
2 (9.5%)
9 (43%)

0.4
.006
0.8
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0.8
0.2
0.2
1.0

0.03

0.6

0.6

pacemaker
Implanted cardiac
19 (45%)
8 (38%)
11 (52%)
0.4
defibrillator
Prior stroke
8 (19%)
4 (19%)
4 (19%)
1.0
Chronic obstructive
17 (41%)
12 (57%)
5 (25%)
0.04
pulmonary disease
Diabetes
19 (45%)
9 (43%)
10 (48%)
0.8
Renal dysfunction
16 (38%)
9 (43%)
7 (33%)
0.5
Medications on discharge
ACE inhibitor
19 (45%)
10 (48%)
13 (62%)
0.4
Antiogensin receptor
6 (14%)
3 (14%)
3 (14%)
1.0
blocker
Beta blocker
36 (86%)
17 (81%)
19 (91%)
0.4
Digoxin
17 (41%)
9 (43%)
8 (38%)
0.8
Diuretic
26 (62%)
16 (76%)
10 (48%)
.06
Antidepressant
17 (41%)
8 (38%)
9 (43%)
0.8
Laboratory values on
admission
B-type natriuretic
746 ± 914
963 ± 1171
529 ± 496
0.2
peptide
BUN
26.2 ± 18.9
31.7 ± 23.6
20.5 ± 9.8
0.06
Creatinine
1.3 ± 1.2
1.5 ± 1.6
1.1 ± 0.43
0.3
Sodium
138.5 ± 6.2
138 ± 5.3
139 ± 7.2
0.7
Beck Depression
16.7 ± 6.7
15.8 ± 6.5
17.6 ± 6.7
0.4
Inventory-II
Minnesota Living with
54 ± 25
50 ± 25
58± 25
0.3
Heart Failure
Questionnaire
Crandell Cognitions
61 ± 19
59 ± 19
64 ± 18
0.5
Inventory
*Data are given as n (%) or mean ± standard deviation unless otherwise indicated.
Independent t-test used to test difference between 2 groups. Chi-square analysis was
used for categorical variables.
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Table 6.3 Primary and secondary outcomes in patients with heart failure

Measure

BDI-II (n = 34)
Baseline
1 week
3 months
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CCI (n = 32)
Baseline
1 week
3 months
MLHFQ (n = 32)
Baseline
1 week
3 months

Least-Squares Mean
(SE)
Brief CT
Usual
Intervention
care

Time

Group x Time

F test

p value

Partial
eta
squared

F test

p value

Partial eta
squared

14.8 (5.5)
9.9 (6.8)
9.3 (5.4)

17.5 (7.3)
14 (9.6)
10.7 (8.8)

16.7

< .001

0.52

.1.0

.38

0.06

61 (20)
56 (23)
54 (23)

64 (20)
68 (25)
59 (22)

3.3

.05

0.19

0.8

.47

0.05

51 (23)
42 (25)
29 (25)

67 (18)
64 (19)
42 (25)

13.7

<.001

0.49

0.5

.59

0.04

CT = Cognitive Therapy, BDI-II = Beck Depression Inventory version II, CCI = Crandell Cognitions Inventory, MLHFQ = Minnesota
Living with Heart Failure Questionnaire

Figure 6.1 Study flow diagram
Assessed for eligibility (n = 407)
Excluded (n = 327)
Did not meet criteria (n = 175)
Declined to participate (n = 20)
Discharged (n = 104)
Other reasons (n = 28)
Consent obtained and patient screened for
depressive symptoms (n = 80)
No depressive symptoms (n = 33)
Mild-moderate symptoms (n = 42)
Severe depressive symptoms (n = 5)

Patients with mild-moderate
symptoms who were
randomized (n = 42)

Allocated to intervention (n = 21)
Received intervention (n = 20)
Withdrawn; cognitive impairment
discovered immediately after
randomization (n = 1)

Allocated to usual care (n = 21)

Unable to contact (n = 1)
-Phone disconnected
Death prior to 3rd assessment (n = 2)
Declined to complete follow-up
assessments (n = 2)
-“Too much work to talk about it”
-Hung up on investigator several times
without speaking

Lost to follow up (n = 1)
-Unable to contact
rd
Did not complete 3 assessment
(n = 1)
-Too busy; during multiple phone
calls stated “not a good time”

Analyzed
Depressive symptoms (n = 18)
Negative thinking (n = 17)
Health-related quality of life (n = 17)
Cardiac event-free survival (n = 20)
Excluded from analysis (n = 1)
-Cognitive impairment; did not meet
inclusion criteria

Analyzed
Depressive symptoms (n = 16)
Negative thinking (n = 15)
Health-related quality of life (n = 15)
Cardiac event-free survival (n = 21)
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Figure 6.2 Change in depressive symptoms over time (n = 34)
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Figure 6.3 Changes in health-related quality of life over time (n = 32)
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Figure 6.4 Changes in negative thinking over time (n = 32)
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Figure 6.3 Kaplan-meier cardiac event-free survival curve (n = 41; log rank test p <
.05).
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CHAPTER SEVEN:
Conclusions
1. Background and purpose
The overall purpose of this dissertation was to develop and test a brief CT
intervention for the treatment of depressive symptoms in patients with HF. The following
manuscripts were completed prior to testing the CT intervention: 1) a review of the
evidence for CT in treating depressive symptoms in patients with cardiovascular-related
conditions,1 2) a qualitative study to describe the experience of living with depressive
symptoms in patients with HF and identify strategies that could be used to manage these
symptoms,2 3) a critical review of the literature to identify a measure of negative thinking
that can be used in patients with HF3, and 4) an evaluation of the psychometric
properties of this measure of negative thinking. Based on findings from these
manuscripts, a randomized, controlled pilot study was conducted to test the effects of a
brief CT intervention on outcomes of hospitalized patients with HF who report depressive
symptoms.
The presence of depressive symptoms is an important clinical problem in
patients with HF. One out of five patients with HF suffers from major depressive
disorder, and an even higher percentage of patients experience self-reported depressive
symptoms.4 Experiencing even mild symptoms of depression place a patient with HF at
higher risk for mortality, morbidity, and worse health-related quality of life.4, 5
Depressive symptoms are under-diagnosed and under-treated in patients with
HF. Up to 40% of patients with HF who have depression are not recognized as
depressed by health care providers.6 The treatment of depression in this population is
complicated by a lack of specific guideline recommendations for depressive symptoms in
patients with HF.7 Although researchers have described the problem of depression in
patients with HF, little is known about which treatments may be effective. Recent
evidence suggests that nursing interventions may be more effective than
antidepressants for the treatment of clinical depression in patients with HF.8 Cognitive
therapy (CT) is an intervention that can be administered by nurses9 and may be an
effective treatment for depressive symptoms in patients with HF.
The purpose of this chapter is to summarize and synthesize the findings of this
dissertation. This chapter will also advance the state of the science of the treatment of
depressive symptoms in patients with heart failure (HF) by making recommendations for
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practice and future research.
2. Summary of findings
Chapter Two is a review of the literature1 on the current evidence for CT
interventions in patients with cardiovascular-related illnesses. Based on limitations of the
studies and mixed results, it was concluded that there is insufficient evidence to
recommend the use of CT for the treatment of depressive symptoms in patients with
cardiovascular conditions. It was recommended that future researchers test CT
interventions in patients with HF via large, randomized, controlled trials that incorporate
the following design elements: the CONSORT guidelines for reporting of clinical trials,
adequate representation of women, long-term follow up (at least one year), and
replicable descriptions of the CT intervention. It was also concluded that research is
needed to determine whether CT is effective for patients with HF who have an acute
exacerbation, the appropriate dose of a CT intervention, and the impact of the
intervention on other outcomes, such as health-related quality of life and cardiovascular
events.
Chapter Three is a qualitative study2 in which patients with HF described the
experience of living with depressive symptoms. This study was nested in a randomized,
controlled trial testing biofeedback and CT in outpatients with HF. The patients described
experiencing negative thoughts such as “I can’t justify my existence,” “I have nothing to
offer anymore,” and “I’m a failure.” The patients stated that “dwelling” on these negative
thoughts worsened their depressed mood. The patients also described using positive
thinking to manage their depressive symptoms, thus providing support for a CT
intervention in this population. The use of a cognitive strategy was an expected finding in
the five participants who received biofeedback and CT in the larger study. However, the
control group participants, who never received a CT intervention, also discussed positive
thinking as a strategy for managing depressive symptoms. This finding suggests that
interventions focused on reducing negative thinking using thought-stopping and
affirmations may be particularly welcomed by patients with HF. However, negative
thinking has never been quantitatively measured in patients with HF.
Chapter Four is a critical review of the literature3 to identify a measure of
negative thinking that has the best potential for use in patients with HF. Three of the
most widely used instruments for measuring negative thinking were reviewed: the
Crandell Cognitions Inventory, Automatic Thoughts Questionnaire, and Cognitive
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Checklist- Depression. The Crandell Cognitions Inventory (CCI) was recommended as
having the highest potential for measuring negative thinking in patients with HF. The CCI
has the advantage of being developed with a clinical population and captures a wide
range of negative thinking content. However, the CCI required psychometric testing
among patients with HF before it can be recommended for use.
Chapter Five is an evaluation of the reliability and validity of the CCI in patients
with HF. Cross-sectional questionnaire data were collected from 179 outpatients with
HF. Cronbach’s alpha was 0.96, indicating adequate internal consistency but probable
redundancy. Corrected item-total correlations were greater than 0.4, indicating adequate
homogeneity. Negative thinking displayed a dose-response relationship with depressive
symptoms. The CCI had a stronger correlation with depressive symptoms than anxiety.
Overall, the results support the reliability and validity of the CCI as a measure of
negative thinking in patients with HF, although a shortened version would be more
practical for use in the clinical setting.
Chapter Six is the RCT testing the brief CT intervention in hospitalized patients
with HF. Forty-two patients with HF who reported mild-moderate depressive symptoms
were randomized to a single, brief CT intervention focused on reducing negative
thoughts with thought-stopping and affirmations, or to usual care control. Although there
were trends toward faster improvement in depressive symptoms, HRQOL and negative
thinking in the intervention group, these trends were not significant. While both groups
improved in all three variables over time, the intervention group experienced longer
cardiac event-free survival and fewer cardiovascular events compared to the control
group. Combined, the results suggest that it is beneficial to administer a brief CT
intervention in the acute care setting to patients with HF who experience mild-moderate
symptoms of depression.
3. Impact of dissertation on the state of the science
There is little evidence supporting non-pharmacological interventions for the
treatment of depressive symptoms in patients with HF. Although researchers and
clinicians had established that depressive symptoms are a significant clinical problem in
patients with HF, no interventions had been shown to improve the negative sequelae
associated with depressive symptoms. The state of the science in treating depressive
symptoms is such that the latest American College of Cardiology and American Heart
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Association guidelines7 did not include specific recommendations for screening or
treatment of depressive symptoms in patients with HF.
I have advanced the state of the science in the treatment of depressive
symptoms in patients with HF by: 1) identifying components that are necessary for the
design of clinical trials that test CT interventions for depressive symptoms in patients
with HF, 2) describing negative thinking as an important target for the treatment of
depressive symptoms in patients with HF, 3) developing a brief CT intervention based on
evidence from the qualitative study, 4) identifying a measure of negative thinking and
providing evidence for its reliability and validity in patients with HF, 5) showing that it is
both practical and beneficial to provide a CT intervention to patients with HF who are
hospitalized, 6) and demonstrating that a nurse-delivered, brief CT intervention improves
cardiac event-free survival in patients with HF.
First, Chapter Two1 identified important design components that are needed in
future clinical trials testing CT treatments for depressive symptoms in patients with HF.
Subsequently, the RCT presented in Chapter Six incorporated these recommendations.
The RCT included recommended design components such as: intentional sampling of
50% females, a scripted, replicable intervention, measurement of HRQOL and cardiac
event-free survival, and following the CONSORT guidelines for reporting the results of
the trial.
Next, in the qualitative study in Chapter Three,2 I identified negative thinking as a
key modifiable target for depressive symptoms in patients with HF. This finding is
consistent with Beck’s cognitive model of depression which posits that negative thinking
influences the emotional, behavioral, and somatic symptoms of depression.10 For
patients in the qualitative study, the most commonly used strategy for managing
depressive symptoms was the use of positive thinking. Positive thinking for these
patients was defined as the redirection of thoughts away from the negative (i.e., thoughtstopping) and focusing instead on affirmations, such as “I’m alive” and “My mind and
soul are strong and healthy.”
Based on the findings from Chapter Three, a brief CT intervention was developed
for use in hospitalized patients with HF who have depressive symptoms. Strategies
discussed by patients comprised four of the six steps of the brief, 30 minute intervention
(Table 1) presented in Chapter Six. These strategies included: understanding the
relationship between stressful situations, negative thinking, and symptoms of
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depression; personal stories told by the patients about how negative thoughts influenced
their feelings and behaviors; thought-stopping or refusing to “dwell” on negative
thoughts; and the use of written and verbal affirmations. A colorful, 13 page flip chart
with photos was developed to guide the script of the intervention, and color booklet
versions were printed for patients to take home. Although a similar CT intervention using
thought-stopping and affirmations has previously been tested in women at risk for
depression,11, 12 this intervention has never been tested in patients with HF. The
intervention tested in this dissertation was particularly innovative because of its brevity
(30 minutes), practicality, and potential to be implemented by nurses in the acute care
setting.
To determine the effectiveness of CT to reduce negative thinking as a treatment
for depressive symptoms in patients with HF, researchers need a valid and reliable
measure of negative thinking in this population. In Chapters Four3 and Five, I advanced
the state of the science in depression and heart failure by identifying an instrument with
the best potential for measuring negative thinking and providing strong evidence for its
reliability and validity in patients with HF. It is recommended that the CCI be used to
measure changes in negative thinking in studies testing CT interventions in patients with
HF. However, the CCI may need to be shortened and undergo further psychometric
testing to make it more practical for the clinical setting.
In the review of the literature presented in Chapter Two,1 I determined that we do
not know whether it is practical or beneficial to offer a CT intervention to patients with HF
who are hospitalized. For example, the ENRICHD investigators13 found that a CT
intervention did not improve survival outcomes in patients with HF who had recently
experienced an acute myocardial infarction. These investigators questioned whether it
was appropriate to administer an intervention after an acute cardiac event. The findings
from our study in Chapter Six suggest otherwise—we found that it is both practical and
beneficial to deliver a brief CT intervention to hospitalized patients with HF.
Finally, this dissertation represents an important contribution to the literature
because it was the first study to show that a nurse-delivered, non-pharmacological
intervention for depressive symptoms in patients with HF is associated with longer
cardiac event-free survival and fewer cardiovascular events compared to usual care.
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4. Recommendations for nursing practice and research
Depressive symptoms are an important predictor of mortality and morbidity in
patients with HF that require intervention. Results from the recent SADHART-HF study8
suggest that nursing interventions may be more effective than antidepressant therapy for
the treatment of depressive symptoms in patients with HF. If future clinical trials provide
additional evidence that antidepressant therapy has limited benefit for patients with HF,
non-pharmacological interventions could emerge as a preferred method of treatment for
depressive symptoms in patients with HF. This however, will also require additional
evidence to demonstrate the effectiveness of non-pharmacological interventions for
depressive symptoms in patients with HF.
The CT intervention tested in this dissertation was designed to be brief (30
minutes) because of the time constraints of nurses working in the acute care setting.
It is recommended that acute care nurses use this brief intervention to improve
outcomes of patients with HF who report depressive symptoms.
Additional studies are planned to expand upon this pilot study. My next step will
be evaluate the psychometric properties of a shortened version of the CCI using data
collected from outpatients (N = 179) and inpatients with HF (N = 80) who enrolled in the
studies described in Chapters Five and Six. After shortening the CCI, I plan to conduct a
large, randomized controlled trial to test the long-term effects of the brief CT intervention
provided to patients who are hospitalized with HF. This study will be adequately powered
to detect differences in all primary and secondary outcomes. Furthermore, the study will
include patients with higher levels of depressive symptoms and incorporate a follow-up
period of at least one year.
Depressive symptoms have important clinical consequences in patients with HF,
and nursing interventions may be an important treatment strategy of the future. This
dissertation has fulfilled an important gap in the evidence base for depression treatment
in patients with HF by demonstrating that a nurse-delivered, brief CT intervention may
improve cardiac event-free survival in patients with HF. This brief CT intervention is
replicable, practical, and can be delivered by acute care nurses to improve clinical
outcomes in patients with HF.

Copyright © Rebecca L. Dekker 2010
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Table 7.1: Summary of the six steps of the brief cognitive therapy intervention
Step 1: Depression and heart failure
Description of symptoms of depression
Depression is common in people with heart failure
Bad news: Depression is bad for the heart
Good news: There are treatments for depression
Discussion question: “Do any of these symptoms of depression sound familiar to
you?”
Step 2: Thoughts, feelings, and behaviors
The connection between thoughts, feelings and behaviors
Thoughts can be false and negative, and these thoughts contribute to painful
feelings and negative behaviors of depression
Two real-life patient stories are told that demonstrate the link between a stressful
situation and negative thinking, feelings, and behaviors
Discussion question: “Do these stories sound familiar to you? Do you see how the
person’s negative thinking led to painful feelings and negative behaviors?”
Step 3: Your story
Interactive component: Patient is asked to describe a recent stressful situation
Discussion questions: “What kind of thoughts were going through your head? How
did these thoughts make you feel? Did you notice any behaviors?”
Step 4: Thought-stopping
Notice you have a negative thought
Snap your fingers or clap your hands and say, “Stop!”
By stopping the negative thought you help take away the painful feelings that go with
the thought
Interactive component: Patient practices the stop technique with the interventionist
Step 5: Affirmations
An affirmation is a short, simple phrase that states how life is at its very best
Use first person, present tense, and positive words; if you have a religious faith you
may use it in your affirmation
Interactive component: The patient comes up with 3-4 affirmations with the help of
the interventionist
The interventionist writes the affirmations on 2 brightly colored sticky notes: one for
the hospital room and one for the patient to take home
Step 6: Homework
Practice the stop technique every time you hear a negative thought
Hang the list of affirmations somewhere you will see it every day
For every negative thought, think at least 2 positive thoughts
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